Ankylosing Spondylitis and Undifferentiated Spondyloarthropathy

Back

Practice Essentials

Ankylosing spondylitis (AS), a spondyloarthropathy, is a chronic, multisystem inflammatory disorder involving primarily the sacroiliac (SI) joints and the axial skeleton. See the image below. The outcome in patients with a spondyloarthropathy, including AS, is generally good compared with that in patients with a disease such as rheumatoid arthritis. 



View Image

Anteroposterior radiograph of sacroiliac joint of patient with ankylosing spondylitis. Bilateral sacroiliitis with sclerosis can be observed.

Non-radiographic axial spondyloarthropathy is a term used to describe patients with predominantly axial features and includes patients with clinical features of AS but with normal plain radiographs of the sacroiliac joints and spin. This disorder probably represents an earlier phase or milder form of AS.

Undifferentiated spondyloarthropathy (USpA) is used to describe patients with predominantly peripheral features and may represent an early phase or incomplete form of AS or another spondyloarthropathy.

Signs and symptoms

Ankylosing spondylitis

Key components of the patient history that suggest AS include the following:

General symptoms of AS include the following:

Fatigue is another common complaint, occurring in approximately 65% of patients with AS. Increased levels of fatigue are associated with increased pain and stiffness and decreased functional capacity.[2, 3]

Extra-articular manifestations of AS can include the following:

Undifferentiated spondyloarthropathy

Clinical manifestations of undifferentiated spondyloarthropathy include the following:

See Clinical Presentation for more detail.

Diagnosis

The diagnosis of AS is generally made by combining the clinical criteria of inflammatory back pain and enthesitis or arthritis with radiologic findings.[4, 5, 6]

Radiography

Radiographic evidence of inflammatory changes in the SI joints and spine are useful in the diagnosis and ongoing evaluation of AS.[7]

Early radiographic signs of enthesitis include squaring of the vertebral bodies caused by erosions of the superior and inferior margins of these bodies, resulting in loss of the normal concave contour of the bodies’ anterior surface. The inflammatory lesions at vertebral entheses may result in sclerosis of the superior and inferior margins of the vertebral bodies, called shiny corners (Romanus lesion).

Power Doppler ultrasonography can be used to document active enthesitis. In addition, this technology may be useful in the assessment of changes in inflammatory activity at entheses during the institution of new therapies.[8]

MRI and CT scanning

Magnetic resonance imaging (MRI) or computed tomography (CT) scanning of the SI joints, spine, and peripheral joints may reveal evidence of early sacroiliitis, erosions, and enthesitis that are not apparent on standard radiographs.[9, 10]

See Workup for more detail.

Management

Pharmacologic therapy

Agents used in the treatment of AS include the following:

Surgical therapy

The following procedures can be used in the surgical management of AS:

See Treatment and Medication for more detail.

Background

Ankylosing spondylitis (AS) is a chronic, multisystem inflammatory disorder primarily involving the sacroiliac (SI) joints and the axial skeleton. Other clinical manifestations include peripheral arthritis, enthesitis, and extra-articular organ involvement.[13, 14, 15, 16] AS has been designated by various names, including rheumatoid spondylitis in the American literature, spondyloarthrite rhizomegalique in the French literature, and the eponyms Marie-Strümpell disease and von Bechterew disease.

AS is the prototype of the spondyloarthropathies, a family of related disorders that also includes reactive arthritis (ReA), psoriatic arthritis (PsA), spondyloarthropathy associated with inflammatory bowel disease (IBD), undifferentiated spondyloarthropathy (USpA), and, possibly, Whipple disease and Behçet disease (see the image below). The spondyloarthropathies are linked by common genetics (the human leukocyte antigen [HLA] class-I gene HLA-B27) and a common pathology (enthesitis).



View Image

Family of spondyloarthropathies and HLA-B27 associated diseases

AS is classified as a spondyloarthropathy. The disorder is often found in association with other spondyloarthropathies, including ReA, PsA, ulcerative colitis (UC), and Crohn disease. Patients often have a family history of either AS or another spondyloarthropathy.

The etiology of AS is not understood completely; however, a strong genetic predisposition exists.[17, 4] A direct relationship between AS and the HLA-B27 gene has been determined.[18, 19, 20, 21] The precise role of HLA-B27 in precipitating AS remains unknown; however, it is believed that HLA-B27 may resemble or act as a receptor for an inciting antigen (eg, a bacterial antigen).

The diagnosis of AS is generally made by combining clinical criteria of inflammatory back pain and enthesitis or arthritis with radiological findings. Early diagnosis is important because early medical and physical therapy may improve functional outcome. As with any chronic disease, patient education is vital to familiarize the patient with the symptoms, course, and treatment of the disease. Treatment measures include pharmacologic, physical therapy, and surgical.

Pathophysiology

The spondyloarthropathies are chronic inflammatory diseases that most commonly involve the SI joints and the axial skeleton, with hip and shoulder joints less frequently affected. Peripheral joints and entheses and certain extra-articular organs, including the eyes, skin, and cardiovascular system, may be involved to a lesser degree.

The primary pathology of the spondyloarthropathies is enthesitis with chronic inflammation, including CD4+ and CD8+ T lymphocytes and macrophages. Cytokines, particularly tumor necrosis factor-α (TNF-α) and transforming growth factor-β (TGF-β), are also important in the inflammatory process by leading to fibrosis and ossification at sites of enthesitis.[22, 23, 24]

The initial presentation of AS generally relates to the SI joints; involvement of the SI joints is required to establish the diagnosis. SI joint involvement is followed by involvement of the discovertebral, apophyseal, costovertebral, and costotransverse joints and the paravertebral ligaments.

Early lesions include subchondral granulation tissue that erodes the joint and is replaced gradually by fibrocartilage and then ossification. This occurs in ligamentous and capsular attachment sites to bone and is called enthesitis.[25]

In the spine, this initial process occurs at the junction of the vertebrae and the anulus fibrosus of the intervertebral discs. The outer fibers of the discs eventually undergo ossification to form syndesmophytes. The condition progresses to the characteristic bamboo spine appearance.

Extra-articular involvement can include acute anterior uveitis and aortitis. Acute anterior uveitis occurs in 25-30% of patients and generally is unilateral. Symptoms include pain, lacrimation, photophobia, and blurred vision. Cardiac involvement including aortic insufficiency and conduction defects is generally a late finding and is rare.[26]

Pulmonary involvement is secondary to inflammation of the costovertebral and costotransverse joints, which limits chest-wall range of motion (ROM). Pulmonary fibrosis is generally an asymptomatic incidental radiographic finding. Neurologic deficits are secondary to spinal fracture or cauda equina syndrome resulting from spinal stenosis. Spinal fracture is most common in the cervical spine.

Etiology

The etiology of AS is unknown, but a combination of genetic and environmental factors works in concert to produce clinical disease.[27]

Genetic predisposition

The strong association of AS with HLA-B27 is direct evidence of the importance of genetic predisposition (see Table 1 below).[18, 19, 20, 28, 29, 30, 31] Of the various genotypic subtypes of HLA-B27, HLA-B*2705 has the strongest association with the spondyloarthropathies. HLA-B*2702, *2703, *2704, and *2707 are also associated with AS.[32] People who are homozygous for HLA-B27 are at a greater risk for AS than those who are heterozygous.[33]

AS is more common in persons with a family history of AS or another seronegative spondyloarthropathy. The concordance rate in identical twins is 60% or less. HLA-B27–restricted CD8+ (cytotoxic) T cells may play an important role in bacterial-related spondyloarthropathies such as reactive arthritis.[34] An epistatic interaction between HLA-B60 and HLA-B27 increases the risk of developing AS.[35]

Table 1. Association of Spondyloarthropathies With HLA-B27



View Table

See Table

The shared amino acid sequence between the antigen-binding region of several HLA-B27 genotypic subtypes, especially HLA-B*2705, and nitrogenase from Klebsiella pneumoniae supports molecular mimicry as a possible mechanism for the induction of spondyloarthropathies in genetically susceptible hosts via an environmental stimulus, including bacteria in the GI tract.[36] The specifics of this relationship remain unclear.

Several other genes have been studied with respect to their potential involvement in the development of AS (see Table 2 below).

Table 2. Genetics of Ankylosing Spondylitis



View Table

See Table

The interleukin (IL)-1 gene cluster is an important locus associated with susceptibility to AS.[37, 38] CYP 2D6 is weakly associated with AS.[29] ARTS1 is also associated with AS. This gene encodes the endoplasmic reticulum aminopeptidase, which cleaves cytokine receptors for IL-6, TNF-α, and IL-1 from the cell surface and is important in antigen presentation by class 1 major histocompatibility complex (MHC) molecules.[39, 30, 31]

IL23R, which encodes the receptor for IL-23, is also associated with AS.[39, 40, 41, 42, 30, 31] IL-23 promotes survival of TH17 CD4+ T cells. TH17 cells play an important role in inflammatory responses by producing various proinflammatory cytokines (eg, IL-17, IL-6, and TNF-α) and recruiting other inflammatory cells (eg, neutrophils) in inflammatory and infectious diseases. Thus, they may play an important role cells in the pathogenesis of AS and other spondyloarthropathies.[43]

Genes possibly associated with ankylosing spondylitis include ANKH and HLA-DRB1.[29]

Numerous genes have been excluded in the etiology of ankylosing spondylitis, such as the following[29] :

Immunologic mechanisms

Another possible mechanism in the induction of AS is presentation of an arthritogenic peptide from enteric bacteria by specific HLA molecules. Many patients with AS have subclinical GI tract inflammation and elevated IgA antibodies directed against Klebsiella. The bacteria may invade the GI tract of a genetically susceptible host, leading to chronic inflammation and increased permeability. Over time, bacterial antigens containing arthritogenic peptides enter the organism via the bloodstream.

Localization of pathology to certain types of connective tissues (eg, entheses) may be explained by affinity of bacterial antigens to these specific sites. Biomechanical stress, such as that which occurs at entheses in the spine and feet, may predispose to clinical enthesitis at these sites.

The spondyloarthropathies are the only known autoimmune diseases linked to an HLA class-I rather than HLA class-II genes. The cytotoxic CD8+ T-cell response appears to be important; it would respond to antigen presented by HLA class-I molecules on the surface of cells. The association of spondyloarthropathies (eg, ReA) with HIV infection in certain areas of the world supports the relative importance of the CD8+ cytotoxic T-cell responses compared with the CD4+ helper cells in these conditions.

Environmental factors

AS does not develop in every person who is HLA-B27 positive; thus, it is clear that environmental factors are important. Even first-degree relatives who are HLA-B27 positive do not uniformly develop the disease. In fact, only 15-20% of such individuals develop the disease.

HLA-B27–positive transgenic rats develop an illness similar to a spondyloarthropathy, with manifestations that include sacroiliitis, enthesitis, arthritis, skin and nail lesions, ocular inflammation, cardiac inflammation, and inflammation of the gastrointestinal and male genitourinary tracts.[44] The severity of the clinical disease correlates with the number of copies of HLA-B27 expressed in the transgenic animal.

HLA-B27–positive transgenic rats that are raised in a germ-free environment do not develop clinical disease. Once introduced into a regular environment (ie, non–germ-free) and exposed to bacteria, the rats develop clinical manifestations of spondyloarthropathy.[45, 46]

Patients with AS may experience exacerbations after trauma. However, no scientific studies support trauma as a cause of AS.

Epidemiology

AS is the most common of the classic spondyloarthropathies. Prevalence varies with the prevalence of the HLA-B27 gene in a given population, which increases with distance from the equator. In general, AS is more common in whites than in nonwhites. It occurs in 0.1-1% of the general population,[47, 48, 49] with the highest prevalence in northern European countries and the lowest in sub-Saharan Africa.[32, 50]

Approximately 1-2% of all people who are positive for HLA-B27 develop AS. This increases to 15-20% if they have a first-degree relative with HLA-B27 positive AS.[4, 27]

Prevalence data for undifferentiated spondyloarthropathy (USpA) are scarce, although this disorder appears to be at least as common as AS, if not more so.[47] Its actual prevalence may be as high as 1-2% of the general population.

Age-related demographics

The age of onset of AS is usually from the late teens to age 40 years. Approximately 10%-20% of all patients experience symptom onset before age 16 years; in such patients, the disease is referred to as juvenile-onset AS. Onset of AS in persons older than 50 years is unusual, although diagnosis of mild or asymptomatic disease may be made at a later age.[51]

There is often a significant delay in diagnosis, usually occurring several years after the onset of inflammatory rheumatic symptoms. In a study of German and Austrian patients with AS, the age of onset of disease symptoms was 25 years in HLA-B27–positive and 28 years in HLA-B27–negative patients, with a delay in diagnosis of 8.5 years in HLA-B27 –positive and 11.4 years in HLA-B27–negative patients.[52]

In a study of Turkish patients with AS, the age of onset of disease symptoms was 23 years, with a delay in diagnosis of 5.3 years in HLA-B27–positive patients and 9.2 years in HLA-B27–negative patients.[53] Patients with inflammatory back pain or a positive family history of AS had a shorter diagnostic delay.

USpA is generally found in young to middle-aged adults but can develop from late childhood into the fifth decade of life.[54]

Sex-related demographics

According to radiographic survey studies, prevalence rates of AS are approximately equal in men and women. However, men have more severe radiographic changes in the spine and hips than women,[55] and clinical AS is more common in men than in women, with a male-to-female ratio of approximately 3:1.[4, 51] Females may have milder or subclinical disease. The male-to-female ratio for USpA is 1:3.[54]

Race-related demographics

The prevalence of AS parallels the prevalence of HLA-B27 in the general population. The prevalence of HLA-B27 and AS is higher in whites and certain Native Americans than in African Americans, Asians, and other nonwhite ethnic groups.[32, 29]  However, a study of racial differences in AS among patients in the United States found that African Americans have high disease activity and co-morbidities compared with whites.[56] AS is least prevalent in sub-Saharan Africa. The less common juvenile-onset version of AS is more common among Native Americans, Mexicans, and persons in developing countries.

USpA is not associated as strongly with HLA-B27, although it is more prevalent in whites than in nonwhite ethnic groups.[54]

 

Prognosis

The outcome in patients with spondyloarthropathies, including AS, is generally good compared with that in patients with a disease such as rheumatoid arthritis. Patients often require long-term anti-inflammatory therapy. Morbidity can occur from spinal and peripheral joint involvement or, rarely, extra-articular manifestations. Indicators of poor prognosis include the following:

At the onset of the disease, symptoms are generally unilateral and intermittent. As the disease progresses, pain and stiffness generally become more severe and more constant. Adequate exercise can improve symptoms and ROM.

Some patients have few, if any, symptoms. A significant portion of AS patients develop chronic progressive disease and develop disability due to spinal inflammation leading to fusion, often with thoracic kyphosis or erosive disease involving peripheral joints, especially the hips and shoulders. Patients with spinal fusion are prone to spinal fractures that may result in neurologic deficits. Most functional loss in AS occurs during the first 10 years of illness.[57]

Severe physical disability is not common among patients with AS. Problems with mobility occur in approximately 47% of patients. Disability is related to the duration of the disease, peripheral arthritis, cervical spine involvement, younger age at onset of symptoms, and coexisting illnesses. Disability has been demonstrated to improve with prolonged periods of exercise or surgical correction of peripheral joint and cervical spine involvement.

Most patients remain fully functional and continue working after the onset of symptoms.[58, 59, 60, 61, 62, 63] Vocational counseling has been demonstrated to decrease the risk of employment disability by more than 60%.[64] Although most patients are able to continue to work, as many as 37% change occupations to less physically demanding jobs as symptoms progress.

In rare cases, patients with severe long-standing AS develop significant extra-articular manifestations such as cardiovascular disease, including cardiac conduction defects and aortic regurgitation; pulmonary fibrosis; neurologic sequelae (eg, cauda equina syndrome); or amyloidosis. Patients with severe long-standing AS have a greater risk of mortality than the general population.[57] Death is more likely in the presence of either extra-articular manifestations or coexisting diseases.[65, 66]

Emotional problems related to the disease are reported in 20% of patients. Depression is more common among women, and contributing factors include the level of pain and functional disability involved.

USpA appears to carry a good-to-excellent prognosis, although some patients have chronic symptoms associated with functional disability. Erosive arthritis is very uncommon. Uveitis occasionally occurs and may be recurrent or chronic. Patients who develop sacroiliitis and spondylitis, by definition, have AS.[67, 54]

Patient Education

Patient education is essential in disease management. Teach patients about the long-term nature of the illness and the use and toxicities of medications. Inform patients that proper exercise programs are useful in reducing symptoms and increasing ROM. For patient education information, see the Ankylosing Spondylitis Directory.

Because of the joint involvement in the chest wall and the potential for pulmonary complications, include smoking cessation in recommendations. One 2011 study found that a history of smoking was associated with higher disease activity and decreased function in AS.[68]

Genetic counseling is useful in assisting patients with questions regarding the risk of family members developing AS or other seronegative spondyloarthropathies. Various patient support groups are available to assist in the education of these patients (eg, Spondylitis Association of America support groups).

History

Key components of the patient history that suggest ankylosing spondylitis (AS) include the following:

General symptoms

Symptoms of AS include those related to inflammatory back pain, peripheral enthesitis and arthritis, and constitutional and organ-specific extra-articular manifestations. Because AS is a systemic inflammatory disease, systemic features are common.

Chronic pain and stiffness are the most common complaints of patients with AS. More than 70% of patients report daily pain and stiffness.[69]

Fatigue is another common complaint, occurring in approximately 65% of AS patients. Most patients report their fatigue to be moderately severe. Increased levels of fatigue are associated with increased pain and stiffness and decreased functional capacity.[2, 3]

Fever and weight loss may occur during periods of active disease.

Inflammatory back pain

Inflammatory back pain is the most common symptom and the first manifestation in approximately 75% of patients.[70] The pain is typically dull and poorly localized to the gluteal and sacroiliac (SI) areas.

Symptoms associated with inflammatory back pain include insidious onset occurring over months or years, generally with at least 3 months of symptoms before presentation. Most patients have mild chronic disease or intermittent flares with periods of remission. The spinal disease is rarely persistently active.

The pain often begins unilaterally and intermittently, and generally begins in the lumbosacral region (SI joints). However, as the disease progresses, it becomes more persistent and bilateral and progresses more proximally,[3] with ossification of the annulus fibrosus that results in fusion of the spine (bamboo spine).

Patients commonly experience morning stiffness lasting at least 30 minutes, improvement of symptoms with moderate physical activity, and diffuse nonspecific radiation of pain into both buttocks. Patients often experience stiffness and pain that awakens them in the early morning, a distinctive symptom not generally found in patients with mechanical back pain.

There have been 2 recent criteria for inflammatory back pain.[71, 72]   New criteria to define inflammatory back pain have been proposed; when 4 of the 5 criteria are present, they yield a sensitivity of 79.6% and a specificity of 72.4%.[72]  These criteria include the following:

Acute onset of pain, exacerbation of symptoms with activity, and radicular radiation of pain suggest a mechanical or degenerative process such as disc disease.

Peripheral enthesitis and arthritis

Peripheral musculoskeletal involvement occurs in 30-50% of all patients. Peripheral enthesitis is the basic pathologic process, involving inflammation at the site of insertion of ligaments and tendons on to bone. This often progresses from erosion and osteitis to ossification, resulting in telltale radiological signs of periosteal new bone formation.

The following sites are commonly involved:

Other sites of involvement include the following:

Enthesopathic lesions tend to be quite painful (eg, the plantar fascia when getting out of bed), especially in the morning. Some of the peripheral arthritis occurs at sites in which the major component is local enthesitis, as suggested by magnetic resonance imaging (MRI).

Joint involvement tends to occur most commonly in the hips, shoulders, and joints of the chest wall, including the acromioclavicular and sternoclavicular joints, and often occurs in the first 10 years of disease. Involvement of the hips and shoulders may result in joint damage with radiographic changes. Involvement of the hips and shoulder joints is more common in persons with juvenile-onset AS than in adult patients with AS.

Other peripheral joints are involved less frequently and to a milder degree, usually as an asymmetric oligoarthritis predominantly involving the lower extremities. Involvement of the temporomandibular joint occurs in approximately 10% of patients. Patients may complain of decreased range of motion (ROM) or jaw pain. Involvement of the costovertebral and costotransverse joints can lead to decreased ROM and restriction in respiration. Patients may complain of difficulty breathing or chest tightness.

Physical Examination

Chronic involvement of the spine eventually can lead to decreases in ROM and fusion of the vertebral bodies. Involvement of the cervical and upper thoracic spine can lead to fusion of the neck in a stooped forward-flexed position (see the images below). This position can significantly limit the patient’s ability to ambulate and look straight ahead.



View Image

Patient with ankylosing spondylitis affecting cervical and upper thoracic spine. Patient's spine has been fused in flexed position.



View Image

Posterior view of patient with ankylosing spondylitis affecting cervical and upper thoracic spine. Patient's spine has been fused in flexed position.

Articular manifestations

Focus the physical examination on active and passive ROM of the axial and peripheral joints. Tenderness in the SI joints is common. Peripheral enthesitis is often identified by tenderness and swelling of tendons and ligamentous insertions.[4]

Spine

Stiffness of the spine and kyphosis resulting in a stooped posture are characteristic of advanced-stage AS. Earlier in the course of the disease, indirect evidence of sacroiliitis and spondylitis may be observed, including tenderness of the SI (elicited by either direct pressure or indirect compression) or a limited spinal ROM. Some patients may have a deformity of the spine, most commonly with a loss of lumbar lordosis and accentuated thoracic kyphosis.

The ROM of the lumbar spine can be assessed using various methods, of which the Schober test is the most popular. (This test is not specific for AS.)

Perform the Schober test by marking a 10-cm length of the lumbar spine (with the patient in the erect position), starting at the fifth lumbar spinous process. Instruct the patient to flex his or her spine maximally. Remeasure the distance between the marks. Normal flexion increases the distance by at least 5 cm.

Loss of chest expansion (< 3-cm difference between minimum and maximum chest diameter) is usually found only in patients with late-stage disease. It is generally not helpful in diagnosis.

Peripheral entheses and joints

Peripheral enthesitis occurs in approximately 33% of patients. These lesions are painful and tender to palpation and may be associated with swelling of the tendon or ligament insertion.

The most common and characteristic peripheral sites of enthesitis are the insertion of the Achilles tendon on the calcaneus and the insertion of the plantar fascia on the calcaneus. Certain anatomic areas may be more prone to enthesitis because of biomechanical stress. Carefully examine patients for tenderness upon palpation.

Enthesitis and synovitis account for some of the peripheral joint involvement. Peripheral joint disease occurs in 33% of patients, most commonly in the hips. Hip involvement usually occurs in the first 10 years of the disease course and is typically bilateral.

Other joints may be involved, including the following:

Peripheral joints are uncommonly involved. When they are involved it is in an asymmetric oligoarticular pattern.

Dactylitis (sausage digit) is very uncommon in patients with AS. Isolated small-joint involvement of the hands, feet, or dactylitis strongly suggests reactive arthritis (ReA), psoriatic arthritis (PsA), or undifferentiated spondyloarthropathy (USpA).

Destructive arthritis may affect the hips or shoulder girdle, which may result in limited range of motion and flexion deformities.

Extra-articular manifestations

Screen for extra-articular manifestations of AS by performing specific examinations (eg, ophthalmologic, cardiac, gastrointestinal [GI]). Such manifestations may include the following:

Uveitis

Uveitis (also called iritis or iridocyclitis) is the most common extra-articular manifestation of AS, occurring in 20-30% of patients.[73, 74] Of all patients with acute anterior uveitis, 30-50% have or will develop AS. The incidence is much higher in individuals who are HLA-B27 positive (84-90%). Patients with uveitis may also have or may develop other spondyloarthropathies, including ReA (5-10%), USpA (2-5%), and PsA (< 1%), although this is less common. Isolated inflammatory bowel disease (IBD) is also associated with uveitis.

The uveitis associated with AS is usually acute in presentation and unilateral, and symptoms include a painful red eye with photophobia, increased lacrimation, and blurred vision. The involvement is usually anterior, rarely including posterior elements. Attacks usually resolve over 2-3 months with treatment, and residual visual impairment is unlikely unless treatment is inadequate or delayed. Recurrences are common.

The uveitis that develops in ReA is similar to the uveitis that develops in AS, whereas the uveitis that develops in PsA and in spondyloarthropathy associated with IBD tends to be more chronic and bilateral and often involves posterior elements.

Cardiovascular involvement

Clinically significant cardiovascular involvement occurs in fewer than 10% of AS patients, typically those with severe long-standing disease. However, subclinical disease can be detected in many patients and may occur as an isolated clinical entity in association with HLA-B27.

Aortitis of the ascending aorta may lead to distortion of the aortic ring, resulting in aortic valve insufficiency. Mitral valve insufficiency rarely occurs. Fibrosis of the conduction system may result in various degrees of atrioventricular block, including complete heart block.

Pulmonary involvement

Restrictive lung disease may occur in patients with late-stage AS, with costovertebral and costosternal involvement that limits chest expansion. Bilateral apical pulmonary fibrosis rarely occurs in the setting of severe disease. These lesions may cavitate and become colonized by bacteria or fungi (eg, Aspergillus), resulting in cough, dyspnea, and hemoptysis.

Renal involvement

Amyloidosis is a very rare complication of AS in patients with severe, active, and long-standing disease. These patients generally have active spondylitis, active peripheral joint involvement, a higher erythrocyte sedimentation rate (ESR), and an increased C-reactive protein (CRP) level. This may result in renal dysfunction with proteinuria and renal insufficiency or failure. Immunoglobulin A (IgA) nephropathy has been reported in association with AS.

Neurologic involvement

Neurologic complications may occur secondary to fractures of a fused spine, which may be very difficult to detect with standard radiography. Patients are also prone to atlantoaxial subluxation, which may result in cervical myelopathy. Cauda equina syndrome may also occur in patients with severe long-standing AS.

Gastrointestinal involvement

Asymptomatic inflammation of the proximal colon and terminal ileum has been observed in as many as 60% of patients with AS and USpA. Patients with established AS only rarely develop Crohn disease or ulcerative colitis.

Metabolic bone disease

Although AS is associated with new bone formation at sites of spinal and peripheral enthesitis, osteopenia and osteoporosis have been documented in patients with long-standing spondylitis, resulting in an increased risk of fracture. Patients with AS who have severe spondylitis and who present with acute exacerbations of back or neck pain should be re-evaluated for possible fracture, especially in the setting of trauma. Standard radiography may not be revealing; computed tomography (CT) or MRI may be required to aid in diagnosis.

Heterotopic bone formation may occur after total hip replacement.

Juvenile ankylosing spondylitis

Juvenile AS is clinically similar to adult AS.[75, 76] In approximately 10-20% of all cases, symptom onset occurs before age 16 years. The male-to-female ratio of 3:1 is similar to that of adults.

Enthesitis is prominent early in the course of the disease, while spinal symptoms and limitation of motion may not be present until several years later. Peripheral arthritis, especially in the lower extremities, and dactylitis are more common in children than in adults. Systemic manifestations (eg, fever, weight loss, anemia, leukocytosis) occur at disease onset in children more frequently than in adults.

Initial radiography findings of the sacroiliac regions and spine are often normal or difficult to interpret in children. These factors make a definitive diagnosis of AS difficult in children. In such cases, the presence of HLA-B27 would be supportive of the diagnosis of a spondyloarthropathy.

Some children exhibit a syndrome of seronegativity, enthesopathy, and arthropathy (SEA) that is clinically similar to USpA. These children often develop AS over time, with typical radiographic changes, usually by early adulthood. A variant, ankylosing tarsitis, is described in children who present with enthesitis in the tarsal region. This can lead to ossification, which results in a characteristic radiographic appearance. When tarsal inflammation is part of the clinical picture in a child or adult, strongly consider one of the spondyloarthropathies.

Undifferentiated spondyloarthropathy

USpA has features consistent with the spondyloarthropathies, but affected patients do not fulfill criteria for any specific spondyloarthropathy.[67, 77]

USpA may represent an early phase or incomplete form of AS or another spondyloarthropathy. In fact, several studies of USpA included many patients who probably should have been diagnosed with AS, ReA, or IBD-associated spondyloarthropathy, which made the clinical description very ambiguous. However, subsequent data suggest that these patients may represent a distinct disease entity on the basis of demographic and clinical criteria.

Although no specific criteria are identified, using modified Amor criteria can be helpful in confirming a clinical diagnosis of USpA (see Table 3 below).[54, 78, 5]

Table 3. Diagnostic Criteria for Undifferentiated Spondyloarthropathy Using Modified Amor Criteria



View Table

See Table

The age of onset for USpA extends over a very wide range, with the peak onset at approximately age 50 years. The male-to-female ratio is 1:3. The onset is usually insidious, and, even after years of active disease, sacroiliitis and spondylitis are either absent or appear very mild on routine radiography.

Clinical manifestations of undifferentiated spondyloarthropathy include inflammatory back pain, buttock pain, enthesitis, peripheral arthritis, dactylitis, and fatigue (see Table 4 below). Extra-articular manifestations are uncommon, occurring in fewer than 10% of patients, and include acute anterior uveitis (1-2%), oral ulcers, rash, nonspecific IBD, pleuritis, and pericarditis.

Table 4. Clinical and Laboratory Features of Undifferentiated Spondyloarthropathy



View Table

See Table

Findings of laboratory studies are generally unremarkable except for the presence of an elevated ESR or CRP level. HLA-B27 antigen is positive only in approximately 20-25% of patients.

These factors, especially the late age of onset, female predominance, and low HLA-B27 positivity, suggest that USpA is distinct from AS and the other classic spondyloarthropathies.

In addition, when these patients are observed over long periods, they rarely develop clinical manifestations or radiographic changes that result in a change of diagnosis. Occasionally, radiographs show evidence of periosteal new bone formation at sites of enthesitis, especially at the insertion of the Achilles tendon or plantar fascia on the calcaneus, or early syndesmophytes on the lumbar spine without bridging.

Although most patients with USpA (>75%) have chronic, active disease and require long-term therapy for ongoing symptoms, some patients have mild and intermittent symptoms that require intermittent symptomatic therapy. These episodes may last from 1-2 weeks to several months, with long asymptomatic periods that do not require therapy.

Most patients respond well to nonsteroidal anti-inflammatory drugs (NSAIDs). The majority maintain good function without progressive disease or clinically significant radiographic changes. A small minority of patients do not respond well to or tolerate NSAIDs. In these patients, treatment progression is similar to that in AS patients, including the use of sulfasalazine, methotrexate, and tumor necrosis factor alpha (TNF-α) antagonists, although no well-designed clinical trials have been conducted on the treatment of USpA.

Complications

Complications may occur from spinal and articular disease or extra-articular manifestations. The most common complications of AS include pain, stiffness, and limited functional disability. All of these complications can be reduced through a proper treatment plan consisting of medications, exercise, and education. Patients with AS often have additional coexisting diseases, including other spondyloarthropathies. IBD is also more common in these individuals.

A small minority of patients develop spinal fusion, which may result in severe kyphosis and limited motion of the spine, including the cervical region. The fused spine is more susceptible to fracture, even with relatively minor trauma. Occasionally, the hip and shoulder joints develop severe arthritis, requiring total joint replacement.

Extra-articular manifestations (eg, recurrent uveitis, cardiovascular involvement, pulmonary involvement, amyloidosis) rarely result in significant morbidity or mortality.

Fracture

The most serious complication related to AS is a vertebral fracture. Vertebral fractures associated with AS are most common in the cervical spine and are usually the result of a minor fall. For a patient with advanced AS, minor trauma is capable of producing an unstable spinal injury with the risk of neurologic injury or death.

Vertebral fractures are more likely to produce spinal instability in an individual with AS than in an individual without AS, because in advanced AS, the fracture occurs as in a long-bone fracture. The fracture disrupts not only the bony elements but also the ligamentous supports that have become ossified. Without the ligamentous support, the spine becomes grossly unstable, and this instability can lead to severe neurologic injury, including paralysis and death.

Proper diagnosis of a vertebral fracture is often delayed because the patient does not realize the need to seek medical help, because the physician fails to consider the possibility of a vertebral fracture after minor trauma, or because the fracture is difficult to visualize on radiography.

In some cases, radiographic diagnosis is made difficult by the presence of osteopenia and spinal deformity. Additionally, immobility of the glenohumeral joint can interfere with the ability to obtain an adequate “swimmer’s view” to visualize the lower cervical spine. In many cases, CT scans are required for assessment of the spine. The possibility of fractures in the transverse plane suggests the need for sagittal reformatting of the images. If visualization is still inadequate, MRI and bone scans may be helpful.

Spondylodiscitis

Spondylodiscitis (also referred to as Andersson lesion) is a destructive discovertebral lesion with an estimated symptomatic prevalence of 1-10% in patients with AS.[79, 80] The prevalence in asymptomatic patients is unknown.

The etiology of spondylodiscitis is debatable. Some authors argue that these lesions are the result of mechanical factors, whereas others believe that the inflammation caused by AS is the source. Each of these possible etiologies is likely capable of producing similar lesions.

Spondylodiscitis can occur at any time, regardless of the severity of AS. Patients generally present with acute-onset localized pain. Pain is exacerbated with movement and is alleviated with rest. These symptoms can be easily differentiated from the normal pain pattern of AS, which is insidious in onset and relieved with motion.

Radiologic evidence of spondylodiscitis varies with the disease progression but can include the following[79, 81] :

Plain radiographs are not always sufficient to identify spondylodiscitis. CT scans, MRI, and bone scans are often helpful in confirming the diagnosis.

The prognosis is generally good with conservative therapy, including rest, administration of NSAIDs, and physical therapy. Surgical treatment is indicated only in cases where there is evidence of spinal instability or neurologic injury.

Approach Considerations

Radiographic studies are most helpful in establishing a diagnosis of ankylosing spondylitis (AS).[85] Computed tomography (CT) and magnetic resonance imaging (MRI) may be useful in selected patients but, for reasons of expense, are not typically part of routine evaluation. For full discussion, see Imaging in Ankylosing Spondylitis.

European League Against Rheumatism (EULAR) guidelines for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice, issued in April 2015, recommend conventional radiography of the sacroiliac (SI) joints as the first imaging method to diagnose sacroiliitis as part of axial spondyloarthritis in the majority of cases. Magnetic resonance imaging (MRI) of the SI joints is an alternative in certain cases, such as young patients and those with short duration of symptoms.[86]

EULAR also recommends MRI of the SI joints for patients in whom clinical features and conventional radiography findings are not diagnostic, but axial spondyloarthritis is still suspected. On MRI, findings to consider include both active inflammatory lesions (primarily bone marrow edema) and structural lesions (eg, bone erosion, new bone formation, sclerosis and fat infiltration).[86]

EULAR does not generally recommend imaging modalities other than conventional radiography and MRI for diagnosing axial spondyloarthropathy. CT may provide additional information on structural damage if conventional radiography is negative and MRI cannot be performed. Scintigraphy and ultrasound (US) are not recommended for diagnosis of sacroiliitis as part of axial spondyloarthropathy.

EULAR recommends initial conventional radiography of the lumbar and cervical spine to detect syndesmophytes in patients with AS. MRI may also be used to predict development of new radiographic syndesmophytes.[86]

Power Doppler ultrasonography can be used to document active enthesitis. In addition, this technology may be useful to assess changes in inflammatory activity at entheses during institution of new therapies.[8]

The diagnosis of AS is not dependent on laboratory data; no laboratory tests are specific for AS. Biopsy and histologic analysis are not indicated for individuals with AS.

Laboratory Studies

Approximately 15% of patients with AS present with a normochromic normocytic anemia of chronic disease. The erythrocyte sedimentation rate (ESR) or the C-reactive protein (CRP) level is elevated in approximately 75% of patients and may correlate with disease activity in some, but not all, patients; these values may also be used as markers of response to treatment.[87, 88]

Alkaline phosphatase (ALP) is elevated in 50% of patients; this indicates active ossification but does not correlate with disease activity. Creatine kinase (CK) is occasionally elevated but is not associated with muscle weakness. The serum immunoglobulin A (IgA) level may be elevated, correlating with elevated acute-phase reactants.

Of white patients with AS, 92% are HLA-B27 positive; the percentage is lower in patients of other ethnic backgrounds. Determining HLA-B27 status is not a necessary part of the clinical evaluation and is not required to establish the diagnosis. However, in patients suspected of having a spondyloarthropathy, determining HLA-B27 status may help support the diagnosis, especially in populations with a low prevalence of HLA-B27.

Radiography

Radiographic evidence of inflammatory changes both in the sacroiliac (SI) joints and in the spine are useful in the diagnosis and ongoing evaluation of the disease process.[7] This disease generally begins in the distal portions of the spine and progresses more proximally with time in a continuous fashion.

Involvement of the SI joint is a requirement for the diagnosis of AS. Sacroiliitis is a bilateral inflammatory condition leading to bony erosions and sclerosis of the joints (see the image below).



View Image

Anteroposterior radiograph of sacroiliac joint of patient with ankylosing spondylitis. Bilateral sacroiliitis with sclerosis can be observed.

The sacroiliitis seen in AS is usually bilateral, symmetric, and gradually progressive over years. The lesions progress from blurring of the subchondral bone plate to irregular erosions of the margins of the SI joints (pseudowidening) to sclerosis, narrowing, and finally fusion. Erosions of the subchondral bone of the SI joint are generally seen earlier in the lower portion of the joint (because this portion is lined by synovium) and on the iliac side (because of the thinner cartilage covering this side of the joint).

The radiographic signs of AS are due to enthesitis, particularly of the anulus fibrosus. Early radiographic signs include squaring of the vertebral bodies caused by erosions of the superior and inferior margins of these bodies, resulting in loss of the normal concave contour of the anterior surface of the vertebral bodies (see the images below). The inflammatory lesions at vertebral entheses may result in sclerosis of the superior and inferior margins of the vertebral bodies, called shiny corners (Romanus lesion).



View Image

Anteroposterior radiograph of spine of patient with ankylosing spondylitis. Ossification of anulus fibrosus at multiple levels and squaring of vertebr....



View Image

Anteroposterior radiograph of spine of patient with ankylosing spondylitis.



View Image

Anteroposterior (left) and lateral (right) radiographs of patient with ankylosing spondylitis.

Ossification of the anulus fibrosus leads to the radiographic appearance of syndesmophytes, which, in AS, are typically marginal. Over time, development of continuous (bridging) syndesmophytes may result in a bamboo spine, which is essentially fused (see the images below).



View Image

Anteroposterior radiograph of spine of patient with ankylosing spondylitis. Ossification of anulus fibrosus can be observed at multiple levels, which ....



View Image

This radiograph of the lumbar spine of a patient with end-stage ankylosing spondylitis shows bridging syndesmophytes, resulting in bamboo spine.



View Image

This radiograph of the cervical spine of a patient with ankylosing spondylitis shows fusion of vertebral bodies due to bridging syndesmophytes.

Spinal disease associated with inflammatory bowel disease (IBD) is similar to AS with bilateral symmetric sacroiliitis and gradually ascending spondylitis and marginal syndesmophytes. On the other hand, reactive arthritis (ReA) and psoriatic arthritis (PsA) typically exhibit asymmetric sacroiliitis and discontinuous spondylitis with nonmarginal syndesmophytes.

Radiographs of other areas may show evidence of enthesitis with osteitis or arthropathy. Radiographs of the pelvis may show ossification of various entheses, such as the iliac crest, ischial tuberosity, and femoral trochanter, which is termed whiskering. Occasionally, the symphysis pubis develops erosive changes (osteitis pubis).

Peripheral entheses may develop radiographic changes, including erosion, periosteal new bone formation, and finally, ossification, especially in the feet at the insertion of the Achilles tendon and the plantar fascia on the calcaneus.

Peripheral joint involvement is most common in the hips and shoulders and may result in uniform joint space narrowing, cystic or erosive changes, deformation, and subchondral sclerosis without osteopenia (see the image below). Heterotopic bone formation may occur after total joint replacement, especially in the hip. Ultimately, peripheral joints may undergo ankylosis. See the radiographs below for an example.



View Image

Radiographs of hand (top) and arm (bottom) of patient with peripheral involvement of ankylosing spondylitis. Fusion of joint spaces and deformity can ....

Patients with AS are vulnerable to cervical spine fractures. Long-standing pain may mask the symptoms of fracture. On radiographs, the distorted anatomy, ossified ligaments, and artifacts may obscure the fracture.

A retrospective case series of 32 patients with AS and cervical spine fractures revealed that in 19 patients (59.4%), a fracture was not identified on plain radiographs.[89] Only 5 patients (15.6%) presented immediately after the injury. Of the 15 patients (46.9%) who were initially neurologically intact, 3 patients had neurologic deterioration before admission. Early diagnosis with appropriate radiologic investigations may prevent possible long-term neurologic cord damage.

Patients with a history of AS who report any recent trauma or an increased level of back or neck pain should be fully evaluated for the possibility of a vertebral fracture and subsequent spinal instability (see the image below).



View Image

Radiograph shows vertebral fracture in patient with ankylosing spondylitis.

MRI and CT

MRI or CT scanning of the SI joints, spine, and peripheral joints may reveal evidence of early sacroiliitis, erosions, and enthesitis that are not apparent on standard radiographs.[9, 10] MRI using fat-saturating techniques such as short tau inversion recovery (STIR) or MRI with gadolinium is sensitive for inflammatory lesions of enthesitis.[90, 91] The so-called MR corner sign, characterized by inflammatory lesions at the corners of vertebral bodies, is common in the thoracolumbar region of the spine in patients with AS.[92]

Investigations of patients with AS using serial MRI over time has shown a link between inflammatory lesions and the later development of syndesmophytes.[93] MRI can be used as an adjunct to evaluate the inflammatory changes and to assess neural compromise (see the image below). However, MRI and CT are not part of the routine evaluation of AS patients, because of their relatively high cost.



View Image

Sagittal MRI of thoracolumbar spine of a patient with ankylosing spondylitis. Degenerative disc disease and bridging osteophytes can be observed at mu....

Patients with a fused spine are prone to fractures, which may be hard to diagnose with standard radiography. CT scanning or MRI may be required to document the presence of a fracture in patients with late-stage spinal disease (see the images below).



View Image

This 15-year-old female patient presented with recent onset of right-sided low back pain. Plain radiography findings were normal.



View Image

MRI of the same patient whose radiography findings were normal (previous image). She underwent further evaluation, including MRI. The MRI (short tau i....

Patients who develop bowel or bladder dysfunction should be evaluated immediately with MRI to assess for possible cauda equina syndrome secondary to spinal stenosis. The presence of cauda equina syndrome is a surgical emergency necessitating decompression within 48 hours to prevent permanent loss of function.

Histologic Findings

Histopathologic evaluation is not generally part of the diagnostic workup in patients with ankylosing spondylitis.

The basic pathologic lesion is inflammation at the enthesis (enthesitis), which occurs at the site of insertion of ligaments and tendons into bone. The histologic picture is that of chronic inflammation with CD4+ and CD8+ T lymphocytes and macrophages. Early AS lesions include subchondral granulation tissue that erodes the joint. Over time, fibrosis and ossification occur, which can be seen radiographically as periostitis and ossification at sites of enthesitis, particularly the SI joints, spine, and heels.

Approach Considerations

No definite disease-modifying treatment exists for individuals with ankylosing spondylitis (AS). Early diagnosis is important. As with any chronic disease, patient education is vital to familiarize the patient with the symptoms, course, and treatment of the disease. Treatment measures include pharmacologic, surgical, and physical therapy.

No drugs have been proved to modify the course of the disease, although tumor necrosis factor alpha (TNF-α) antagonists appear to have potential as disease-modifying agents.[94] Symptoms are generally not affected by pregnancy or childbirth. Medical management of AS, including medications, must be adjusted during pregnancy in accordance with the specific pregnancy profiles of the medications.

Inpatient care is generally not necessary for patients with AS. The exceptions to this include patients with coexisting or extra-articular disease and those requiring surgery.

Extra-articular manifestations, which may necessitate specialist referral for appropriate care, include the following:

Disease progress and response to therapy can be monitored by following laboratory values, including the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level.

Surgical treatment is geared toward resolution of the complications related to AS; it is occasionally useful for correcting spinal deformities or repairing damaged peripheral joints. Patients with fusion of the spine secondary to AS who report a change in position of the spine should be cautiously treated and should be considered to have sustained a spinal fracture. Surgical intervention may be necessary to stabilize the fracture and prevent neurologic deficit.[95, 96]

Outpatient care should be aimed toward providing adequate pain control and maximizing motion and functional ability. Such care includes pain medication, exercise programs, recreational therapy, and vocational therapy. Regular exercise helps reduce the symptoms and may slow the progress of the disease. Generally, no dietary restrictions are implemented for patients with AS; however, patients with coexisting diseases, such as inflammatory bowel disease (IBD), have dietary restrictions.

Peripheral spondyloarthritis

Pharmacologic treatment for peripheral spondyloarthritis includes the following:

In a study of adult patients with recent-onset peripheral spondyloarthritis (symptom duration < 12 weeks), early use of the TNF-α inhibitor golimumab resulted in sustained clinical remission in 49 of 60 patients (82%). Most patients (n=30) fulfilled criteria for sustained clinical remission by week 24. On follow-up at least 18 months after drug withdrawal, 26 of the 49 patients (53%) were still in drug-free remission.[97, 98]

Nonradiographic axial spondyloarthritis

In March 2019, the US Food and Drug Administration (FDA) approved certolizumab for treatment of nonradiographic axial spondyloarthritis (nr-axSpA) with objective inflammation. Certolizumab is the first therapy approved for nr-axSpA.

Approval was based on data from the phase 3 C-AXSPAND study, which favored certolizumab over placebo at both week 12 and week 52. At week 52, major improvement in the Ankylosing Spondylitis Disease Activity Score (ASDAS) had occurred in 42% of patients receiving certolizumab, compared with 7% of those receiving placebo.[99]

Pharmacologic Therapy

Nonsteroidal anti-inflammatory drugs

Nonsteroidal anti-inflammatory drugs (NSAIDs) improve the symptoms of the disease by reducing pain and decreasing inflammation. Numerous choices are available, and they are separated into different families of agents.[100] If one NSAID is ineffective, another from a different family can often provide relief.

Efficacy and adverse effect profiles differ among agents and families. Indomethacin may be more effective than other NSAIDs, although this potential advantage has not been proved. Salicylates seldom give adequate relief. Cyclooxygenase-2 (COX-2) inhibitors appear to be as effective as nonselective NSAIDs.[101]

Sieper et al, in a randomized, double-blind, controlled study comparing two dosages of celecoxib (200 mg once daily and 200 mg twice daily) to diclofenac (75 mg twice daily), noted that both dosages of celecoxib were comparable to the diclofenac dosage with respect to global pain intensity.[102] However, with respect to changes in disease activity, functional and mobility capacities, and adverse events, once-daily celecoxib was not as effective in reducing certain inflammation-associated parameters as twice-daily celecoxib and diclofenac were.

Give NSAIDs in full anti-inflammatory doses. Continuous treatment with NSAIDs appears to reduce radiographic progression in AS.[101] Common toxicities involve the gastrointestinal (GI) tract (nausea, dyspepsia, ulceration, bleeding), the kidneys, and the central nervous system (CNS).

Sulfasalazine

Sulfasalazine is useful in AS patients who do not respond to or who have contraindications to NSAIDs, as well as in those with coexisting IBD. In particular, it is often given to treat peripheral joint involvement, for which it has demonstrated efficacy. Sulfasalazine reduces spinal stiffness, peripheral arthritis, and the erythrocyte sedimentation rate (ESR), but there is no evidence that it improves spinal mobility, enthesitis, or physical function.[103, 104, 105] In a randomized, double-blind study, treatment with sulfasalazine resulted in significantly lesser improvement when compared to treatment with the TNF inhibitor etanercept.[106] Sulfasalazine toxicities include rash, nausea, diarrhea, and agranulocytosis (rarely).

TNF-α antagonists

TNF is a cytokine with two identified forms, which have similar biologic properties. TNF-α (cachectin) is produced predominantly by macrophages, and TNF-β (lymphotoxin) is produced by lymphocytes. TNF is but one of many cytokines involved in the inflammatory cascade that may contribute to the symptoms of AS.[107, 100]

TNF-α antagonists have been shown to be very effective in the treatment of AS.[108] They have a fairly rapid onset of action (2 weeks), and have been shown to reduce the inflammatory activity of spinal disease as assessed with magnetic resonance imaging (MRI).[109]

The European League Against Rheumatism notes that extensive MRI inflammatory activity, particularly in the spine, might be used as a predictor of good clinical response to anti-TNF-alpha treatment in patients with AS. Thus, MRI might aid in the decision of initiating anti-TNF-alpha therapy, in addition to clinical examination and C-reactive protein (CRP) testing.[86]

TNF-α antagonists are indicated after NSAID therapy has failed.[94] The following TNF-α antagonists have been approved by the US Food and Drug Administration (FDA) as therapies for AS:

TNF-α antagonists are also approved for the treatment of rheumatoid arthritis and psoriatic arthritis (PsA). Other approved indications include the following:

Toxicities associated with TNF-α antagonists include injection-site and infusion reactions. Increased risks of bacterial infections, reactivation of latent tuberculosis, and certain fungal infections (eg, histoplasmosis, coccidioidomycosis) have been observed.

There is some concern regarding an increased risk of malignancy in patients receiving TNF-α antagonists. The most attention has been focused on lymphoma and nonmelanotic skin cancers in patients with rheumatoid arthritis, although this has been difficult to document in such patients and has not been described in patients with AS. In rare cases, cytopenias have been associated with TNF-α antagonists.

Patients with rheumatoid arthritis who have recently started TNF-α antagonists may be at increased risk for new-onset congestive heart failure even in the absence of any obvious risk factors for the disease. These agents should not be initiated in patients with uncompensated congestive heart failure.

Patients should be screened for latent tuberculosis, hepatitis B, and HIV infection before beginning TNF-α antagonist therapy.[119] Although these agents should not be used in patients with active hepatitis B infection, they appear to be safe in patients with chronic hepatitis C infections. Rarely, autoimmune syndromes (eg, a lupuslike illness) have been noted in patients receiving TNF-α antagonists. More commonly, a positive antinuclear antibody (ANA) test result may occur during treatment without clinical disease.

Demyelinating syndromes have rarely been documented in patients receiving TNF-α antagonists, though no direct link has been proved. These agents should not be used in patients with multiple sclerosis or other demyelinating diseases. New-onset psoriatic skin lesions have been documented after initiation of TNF-α antagonists.

In a prospective study of 334 patients with AS, response to treatment with TNF-α inhibitors was associated with a 50% reduction in the risk of radiographic progression of AS. However, nearly 4 years of treatment were necessary for the benefit to become apparent. Moreover, in patients who first began TNF-inhibitor treatment 10 or more years after disease onset, AS progression was twice as likely as it was in patients who started treatment earlier.[120, 121]

Interleukin inhibitors

Secukinumab (Cosentyx) is a human IgG1 monoclonal antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin 17A (IL-17A). IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Secukinumab was approved by the FDA for adults with active AS in January 2016.

Approval of secukinumab for AS was based on 2 phase 3 trials (MEASURE 1 and 2). In MEASURE 1 (n=371), the Assessment of Spondyloarthritis International Society (ASAS20) response rates at week 16 were 61%, 60%, and 29% for secukinumab doses of 150 mg and 75 mg subcutaneously and for placebo, respectively (P< 0.001 for both comparisons with placebo). In MEASURE 2 (n=219), the rates were 61%, 41%, and 28% for secukinumab doses of 150 mg and 75 mg and for placebo, respectively (P< 0.001 for the 150-mg dose and P=0.10 for the 75-mg dose). The significant improvements were sustained through 52 weeks.[122]

Ixekizumab (Taltz) also targets IL-17A. In August 2019, it was approved by the FDA for adults with active AS. Approval was based on two phase 3 trials (COAST-V and COAST-W) that included 657 adults with active AS. In COAST-V, patients who had not been treated with biological DMARDs were randomized to ixekizumab 80 mg SC every 2 or 4 weeks, adalimumab 40 mg every 2 weeks, or placebo. At week 16, compared with placebo (16 [18%] of 87), more patients achieved improvement with ixekizumab every 2 weeks (43 [52%] of 83; P< 0.0001), ixekizumab every 4 weeks (39 [48%] of 81; P < 0.0001), and adalimumab (32 [36%] of 90; P = 0.0053).[123]

In the COAST-W trial, patients with active AS with a previous inadequate response or intolerance to TNF inhibitors showed a statistical improvement at 16 weeks with ixekizumab. Results showed ixekizumab 80 mg every 2 weeks (30.6%; p = 0.003) and 80 mg every 4 weeks plus initial 160 mg dose (25.4; p = 0.017) respectively showed improvement in AS signs and symptoms compared with placebo (12.5%).[124]

Corticosteroids

Oral corticosteroids are occasionally helpful in controlling AS symptoms. However they should be used only for short-term management; long-term management carries a high risk of adverse effects. No evidence has shown that corticosteroids alter the outcome of the disease, and these agents are known to increase the tendency toward spinal osteoporosis.

Local corticosteroid injections are useful for symptomatic sacroiliitis, peripheral enthesitis, and arthritis, although the response is not typically as rapid as in patients with rheumatoid arthritis.

Other agents

Anecdotal reports suggest that other medications may be helpful in the treatment of AS, including methotrexate, azathioprine, cyclophosphamide, and cyclosporine. Methotrexate is of questionable benefit in AS; various studies have shown conflicting results.[125] At present, it is reserved for patients with symptoms that are not adequately controlled with NSAIDs or sulfasalazine.

Leflunomide was evaluated in a randomized, double-blind, placebo-controlled study in active AS but was not found to be effective.[126] Bisphosphonates may modestly affect clinical disease activity in AS. Anakinra, a recombinant human IL-1 receptor antagonist, may be effective in treatment-resistant AS.

Guideline-directed Therapy

Guidelines on treatment for ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis have been issued by the American College of Rheumatology.[127]

In adults with active AS:

In adults with active AS despite treatment with NSAIDs :

In adults with AS and inflammatory bowel disease :

Other recommendations:

Guidelines issued by an international task force on treating axial and peripheral spondyloarthritis to target include the following recommendations[128] :

Treatment of Uveitis

Acute anterior uveitis presents as a painful red eye that is associated with photophobia and often recurs. Untreated uveitis may lead to vision loss. Evaluation and treatment of uveitis should be performed under the guidance of an ophthalmologist.

Generally, patients respond well to topical corticosteroids, mydriatics, and artificial tears, with resolution of the attack over 2-3 months. Treatment occasionally requires topical NSAIDs, retrobulbar corticosteroid injections, or immunosuppressive drugs. TNF-α antagonists may be helpful in selected cases. A study by van Denderen and colleagues reported a significant reduction in the recurrence rate of anterior uveitis in patients with AS who were treated with adalimumab.[129]

Evaluation of Disease Activity and Treatment Response

Laboratory values, including the ESR and the C-reactive protein (CRP) level, are commonly employed to monitor the progression of the disease and the effectiveness of treatment. Guidelines from the European League Against Rheumatism (EULAR) recommend that conventional radiography of the sacroiliac (SI) joints, spine, or both may be used for long-term monitoring of structural damage, particularly new bone formation. If performed, it should not be repeated more frequently than every second year.[86]

MRI may provide additional information. MRI of the SI joints and/or the spine may be used to assess and monitor disease activity in axial spondyloarthropathy. In general, short tau inversion recovery (STIR) sequences are sufficient to detect inflammation, and the use of contrast medium is not needed.[86]

In addition, numerous tools have been developed to measure AS disease activity, especially in the setting of clinical trials.[130, 131, 132] These tools include the following:

The ASAS response criteria are used to assess improvement in AS in clinical trials. Each of four domains is scored by the patient on a visual analog scale ranging from 0 to 10. The four domains are as follows:

An ASAS20 response is defined as an improvement of at least 20% and an absolute improvement of at least 1 unit (on a 0-10 scale) in at least three of four domains, with no worsening of the remaining domain. An ASAS40 response is similar but requires a 40% improvement. An ASAS partial remission is defined as values of less than 2 for all four ASAS20 domains.

ASAS5/6 includes the four domains included in the ASAS20 plus spinal mobility (BASMI) and acute-phase reactants (CRP). An ASAS5/6 response is defined as improvement of at least 20% and an improvement of at least 1 unit in at least five of six domains, with no worsening of the remaining domain.

Surgical Correction and Stabilization

Surgical interventions for AS include the following:

Vertebral osteotomy

Patients with fusion of the cervical or upper thoracic spine may have significant impairment in line of sight, eating, and psychosocial well-being. These patients may benefit from extension osteotomy of the cervical spine.[11] This procedure is difficult and hazardous and should be performed only by surgeons specializing in spine surgery who have experience with the operation. The risk of major neurologic morbidity is significant; however, if the procedure is successful, it allows the patient to return to a more functional life.

Fracture stabilization

Many patients with advanced disease have fusion of the spine. If these patients report any change in position or movement of the spine, they should be assumed to have a spinal fracture because such an injury is the only way for a fused spine to move. Patients should be treated cautiously until fracture has been ruled out. If spinal fracture is present, surgical stabilization may be necessary.

Joint replacement

Patients with significant involvement of the hips may benefit from total hip arthroplasty[12] ; occasionally, total shoulder replacement may be indicated. These procedures may be very useful for reducing pain and improving function when the hip and shoulder joints become severely damaged. However, patients with AS at increased risk for complications after total hip arthroplasty, as the alteration in biomechanics resulting from spinal rigidity and kyphosis place higher demands on hip joints.[133]

Heterotopic bone formation may occur after total joint replacement, especially around the hip. Heterotopic bone formation can be reduced by giving NSAIDs (eg, indomethacin) or employing radiation therapy postoperatively. In general, outcomes of total joint replacement in patients have been satisfactory.

Physical Therapy and Exercise

Physical therapy is important for maintaining function.[134, 135] A proper exercise program is a crucial component of such therapy. Patients obtain a significant reduction in symptoms after exercising. Referral to physical therapy or to a rehabilitation specialist is useful in assisting patients to develop an appropriate exercise program.  

Water therapy and swimming are excellent activities for maintaining mobility and fitness. In addition, a meta-analysis concluded that aquatic physical therapy can statistically significantly reduce pain and disease activity in patients with AS.[136]

Postural training is also useful. Spinal extension and deep-breathing exercises help maintain spinal mobility, encourage erect posture, and promote chest expansion. Maintaining an erect posture during daily activities and sleeping on a firm mattress with a thin pillow also tend to reduce the tendency toward thoracic kyphosis.

Consultations

Consultations with the following specialists may be appropriate:

Medication Summary

The goal of pharmacotherapy is to reduce morbidity and to prevent complications—specifically, by reducing the pain and inflammation associated with ankylosing spondylitis (AS).

Indomethacin (Indocin)

Clinical Context:  Indomethacin is thought to be the most effective NSAID for the treatment of AS, although no scientific evidence supports this claim. It is used for relief of mild to moderate pain; it inhibits inflammatory reactions and pain by decreasing the activity of COX, which results in a decrease of prostaglandin synthesis.

Ibuprofen (Advil, Motrin)

Clinical Context:  Ibuprofen is used for relief of mild to moderate pain; it inhibits inflammatory reactions and pain by decreasing the activity of COX, which results in a decrease of prostaglandin synthesis.

Naproxen (Naprosyn, Naprelan, Aleve, Anaprox)

Clinical Context:  Naproxen is used for relief of mild to moderate pain; it inhibits inflammatory reactions and pain by decreasing the activity of COX, which results in a decrease of prostaglandin synthesis.

Diclofenac (Voltaren, Zipsor, Cambia)

Clinical Context:  Diclofenac inhibits prostaglandin synthesis by decreasing COX activity, which, in turn, decreases formation of prostaglandin precursors.

Class Summary

Nonsteroidal anti-inflammatory drugs (NSAIDs) are useful for reducing pain secondary to inflammation and systemic symptoms in AS patients. These agents reduce inflammatory symptoms of spinal and peripheral joint pain and morning stiffness and appear to have a modest disease-modifying effect on spinal disease. Cyclooxygenase-2 (COX-2) inhibitors appear to be as effective as traditional NSAIDs.

NSAIDs and COX-2 inhibitors may increase the risk of serious cardiovascular thrombotic events, myocardial infarction (MI), and stroke, which can be fatal. They also increase the risk of serious adverse gastrointestinal (GI) effects, including stomach or intestinal bleeding, ulceration, and perforation, which can also be fatal. Elderly patients are at greater risk for serious GI events.

Sulfasalazine (Azulfidine, Azulfidine EN-tabs)

Clinical Context:  Sulfasalazine has been shown to reduce the inflammatory symptoms of AS in controlled studies; its most common toxicities include nausea, diarrhea, and hypersensitivity reactions (rash).

Class Summary

5-Aminosalicylic acid derivatives inhibit prostaglandin synthesis and reduce the inflammatory response to tissue injury.

Secukinumab (Cosentyx)

Clinical Context:  Human IgG1 monoclonal antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin 17A (IL-17A). IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. It is indicated for adults with active ankylosing spondylitis.

Ixekizumab (Taltz)

Clinical Context:  Humanized monoclonal IgG4 antibody that targets interleukin-17A (IL-17A) and neutralizes the proinflammatory effects of IL-17A. It is indicated for adults with active ankylosing spondylitis.

Class Summary

Various interleukins play a role in inflammatory processes.

Etanercept (Enbrel, Erelzi, etanercept-szzs)

Clinical Context:  Etanercept consists of a fusion protein of the extracellular portion of the p75 TNF-α receptor and the Fc portion of immunoglobulin G (IgG). It inhibits TNF-α, reducing inflammation and symptoms of ankylosing spondylitis. It is given as a subcutaneous (SC) injection and is available in a prefilled syringe, an autoinjector, or lyophilized powder. It is also approved for rheumatoid arthritis, PsA, psoriasis, and juvenile idiopathic arthritis.

Infliximab (Remicade, Inflectra, infliximab-dyyb, Renflexis, infliximab-abda, Ixifi, infliximab-qbtx)

Clinical Context:  Infliximab is a chimeric IgG1κ monoclonal antibody (mAb) directed against TNF-α. The variable regions of heavy and light chains are murine in origin, and the constant regions are human. Infliximab inhibits TNF-α, reducing inflammation and symptoms of AS. It is given as an intravenous (IV) infusion. It is also approved for rheumatoid arthritis, PsA, psoriasis, and Crohn disease.

Adalimumab (Amjevita, Cyltezo, Humira, Hadlima, Hyrimoz, Adalimumab-atto, Adalimumab-adbm, Adalimumab-bwwd, Adalimumab-adaz)

Clinical Context:  Adalimumab is a human IgG1κ mAb directed against TNF-α. It inhibits TNF-α, reducing inflammation and symptoms of AS. It is given as an SC injection and is available in a prefilled syringe or an autoinjector. It is also approved for rheumatoid arthritis, PsA, psoriasis, juvenile idiopathic arthritis, and Crohn disease. FDA approved adalimumab-atto, adalimumab-adbm, adalimumab-adaz, adalimumab-bwwd as biosimilars and not as interchangeable drugs.

Golimumab (Simponi)

Clinical Context:  Golimumab is a human IgG1κ mAb directed against TNF-α. It inhibits TNF-α, reducing inflammation and symptoms of AS. It is given as an SC injection and is available in a prefilled syringe or an autoinjector. It is also approved for rheumatoid arthritis and PsA.

Certolizumab pegol (Cimzia)

Clinical Context:  Certolizumab pegol is a recombinant humanized anti-human TNF-α neutralizing antibody. It inhibits TNF-α, reducing inflammation and symptoms of ankylosing spondylitis. It is given as a subcutaneous injection and is available as a powder for injection. It is FDA-approved for active ankylosing spondylitis, and is also indicated for Crohn Disease, rheumatoid arthritis, and psoriatic arthritis.

Class Summary

Tumor necrosis factor alpha (TNF-α) antagonists are biologic agents and include etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol. These agents inhibit TNF-α and have been shown to improve symptoms and function in AS patients in clinical trials. All have been approved for the treatment of AS. These agents are also all approved for the treatment of rheumatoid arthritis and psoriatic arthritis (PsA).

Methotrexate (Trexall, Otrexup, Rasuvo)

Clinical Context:  Methotrexate has an unknown mechanism of action in AS; it may affect immune function. Effects are observed in the 3-6 weeks following administration. Methotrexate ameliorates symptoms (eg, pain, swelling, stiffness), but there is no evidence that it induces remission. Adjust the dose gradually to obtain a satisfactory response.

Class Summary

Immunosuppressants inhibit key factors in the immune system that are responsible for inflammatory responses.

What are ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?What are the signs and symptoms of ankylosing spondylitis (AS)?What are some signs and symptoms of undifferentiated spondyloarthropathy (USpA)?How is ankylosing spondylitis (AS) diagnosed?What is the role of radiography in the diagnosis of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?What is the role of MRI and CT scanning in the diagnosis of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?Which medications are used in the treatment of ankylosing spondylitis (AS)?Which surgical procedures are performed in the treatment of ankylosing spondylitis (AS)?What is the ankylosing spondylitis (AS)?What is the pathophysiology of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?What is the disease progression of ankylosing spondylitis (AS)?What causes ankylosing spondylitis (AS)?What is the role of genetics in the etiology of ankylosing spondylitis (AS)?Which genes have been excluded in the etiology of ankylosing spondylitis (AS)?Which immunologic mechanisms are involved in the etiology of ankylosing spondylitis (AS)?Which environmental factors are involved in the etiology of ankylosing spondylitis (AS)?What is prevalence of ankylosing spondylitis (AS)?How does the prevalence of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA) vary by age?How does the prevalence of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA) vary by sex?What are the racial predilections for ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?What is the prognosis of ankylosing spondylitis (AS)?What are the causes of disability in ankylosing spondylitis (AS)?What is the prognosis of undifferentiated spondyloarthropathy (USpA)?What should be included in patient education about ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?Which history findings suggest ankylosing spondylitis (AS))?What are the general symptoms of ankylosing spondylitis (AS)?How is inflammatory back pain affect characterized in ankylosing spondylitis (AS)?What is peripheral enthesitis and how does it progress in ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?Which sites are involved in peripheral enthesitis in ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?How are joints affected by peripheral enthesitis in ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?Which physical findings suggest ankylosing spondylitis (AS)?How should the physical exam be focused in the evaluation of ankylosing spondylitis (AS)?Which results of spine exam suggest ankylosing spondylitis (AS)?What are the physical findings of peripheral entheses in ankylosing spondylitis (AS)?What are the extra-articular manifestations of ankylosing spondylitis (AS)?What is the significance of a finding of uveitis in ankylosing spondylitis (AS)?How is uveitis characterized in ankylosing spondylitis (AS)?Which cardiovascular findings suggest ankylosing spondylitis (AS)?Which pulmonary findings suggest ankylosing spondylitis (AS)?Which renal findings suggest ankylosing spondylitis (AS)?Which neurologic findings suggest ankylosing spondylitis (AS)?Which GI findings suggest ankylosing spondylitis (AS)?What are the findings of metabolic bone disease suggestive of ankylosing spondylitis (AS)?What is juvenile ankylosing spondylitis (AS)?Which physical findings suggest juvenile ankylosing spondylitis (AS)?What is the clinical presentation of undifferentiated spondyloarthropathy (USpA)?How is undifferentiated spondyloarthropathy (USpA) diagnosed?What are complications that of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?How do fractures affect patients with ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?How are fractures screened for in patients with ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?What is the presentation of spondylodiscitis in ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?How is spondylodiscitis screened for in patients with ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?What are the diagnostic criteria for ankylosing spondylitis (AS)?What are the New York diagnostic criteria for ankylosing spondylitis (AS)?Which conditions should be included in the differential diagnoses for ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?How is spondyloarthropathy (SpA) classified?What are the Assessment of SpondyloArthritis International Society (ASAS) diagnostic criteria for axial spondyloarthropathy (SpA)?What are the features of axial spondyloarthropathy (SpA)?What are the features of peripheral spondyloarthropathy (SpA)?What are the differential diagnoses for Ankylosing Spondylitis and Undifferentiated Spondyloarthropathy?What are the European League Against Rheumatism (EULAR) guidelines for the use of imaging in the diagnosis and management of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?What is the role of lab studies in the workup of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?What is the role of radiography in the diagnosis and ongoing evaluation of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?Which findings on radiography are diagnostic of ankylosing spondylitis (AS)?What are the early radiographic signs of ankylosing spondylitis (AS)?What are the radiographic findings of the pelvis and limbs suggestive of ankylosing spondylitis (AS)?What is the role of MRI and CT scanning in the workup of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?How is MRI and CT scanning beneficial in the evaluation of ankylosing spondylitis (AS) in patients with fused spines?What is the role of MRI and CT scanning in the evaluation of ankylosing spondylitis (AS) in patients with bowel or bladder dysfunction?Which histologic findings are characteristic of ankylosing spondylitis (AS)?What are the treatment options for ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?What is the role of nonsteroidal anti-inflammatory drugs in the treatment of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?What is the role of sulfasalazine in the treatment of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?What is the role of TNF-? antagonists in the treatment of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?What are the risks and benefits of TNF-? antagonists for the treatment of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?What is the role of interleukin inhibitorsi n the treatment of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?What is the role of corticosteroids in the treatment of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?Which drugs lack evidence of effectiveness in the treatment of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?Which organization has issued treatment guidelines for ankylosing spondylitis (AS)?What are the American College of Rheumatology treatment guidelines for adults with active ankylosing spondylitis (AS)?What are the American College of Rheumatology treatment guidelines for active ankylosing spondylitis (AS) despite treatment with NSAIDs?What are the American College of Rheumatology treatment guidelines for ankylosing spondylitis (AS) in patients with inflammatory bowel disease?What are the American College of Rheumatology treatment guidelines for stable ankylosing spondylitis (AS)?How is uveitis treated in ankylosing spondylitis (AS)?How is disease activity and treatment response evaluated in ankylosing spondylitis (AS)?Which tools are used to measure ankylosing spondylitis (AS) disease activity?What are the Assessment of SpondyloArthritis International Society (ASAS) response criteria?What is the role of surgery in the treatment of ankylosing spondylitis (AS)?What is the role of vertebral osteotomy in the treatment of ankylosing spondylitis (AS)?What is the role of fracture stabilization in the treatment of ankylosing spondylitis (AS)?What is the role of joint replacement in the treatment of ankylosing spondylitis (AS)?What is the role of physical therapy and exercise in the treatment of ankylosing spondylitis (AS)?Which specialist consultations are helpful in the treatment of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?What are the goals of drug treatment for ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?Which medications in the drug class Immunosuppressants are used in the treatment of Ankylosing Spondylitis and Undifferentiated Spondyloarthropathy?Which medications in the drug class DMARDs, TNF Inhibitors are used in the treatment of Ankylosing Spondylitis and Undifferentiated Spondyloarthropathy?Which medications in the drug class Interleukin Inhibitors are used in the treatment of Ankylosing Spondylitis and Undifferentiated Spondyloarthropathy?Which medications in the drug class 5-Aminosalicylic Acid Derivatives are used in the treatment of Ankylosing Spondylitis and Undifferentiated Spondyloarthropathy?Which medications in the drug class Nonsteroidal Anti-inflammatory Drugs are used in the treatment of Ankylosing Spondylitis and Undifferentiated Spondyloarthropathy?

Author

Lawrence H Brent, MD, Associate Professor of Medicine, Sidney Kimmel Medical College of Thomas Jefferson University; Chair, Program Director, Department of Medicine, Division of Rheumatology, Albert Einstein Medical Center

Disclosure: Stock ownership for: Johnson & Johnson.

Coauthor(s)

Anand Patel, MD, Fellow, Department of Rheumatology, Temple University Hospital

Disclosure: Nothing to disclose.

Ruchika Patel, MD, Attending Physician, Division of Rheumatology, Einstein Medical Center

Disclosure: Nothing to disclose.

Chief Editor

Herbert S Diamond, MD, Visiting Professor of Medicine, Division of Rheumatology, State University of New York Downstate Medical Center; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital

Disclosure: Nothing to disclose.

Additional Contributors

Rajni Kalagate, MD, Resident Physician, Department of Internal Medicine, Albert Einstein Medical Center

Disclosure: Nothing to disclose.

Acknowledgements

Jason C Eck, DO, MS Assistant Professor, Department of Orthopedics and Physical Rehabilitation, UMass Memorial Medical Center

Jason C Eck, DO, MS is a member of the following medical societies: American Osteopathic Academy of Orthopedics, American Osteopathic Association, International Society for the Study of the Lumbar Spine, and North American Spine Society

Disclosure: Medtronic Honoraria Speaking and teaching

Elliot Goldberg, MD Dean of the Western Pennsylvania Clinical Campus, Professor, Department of Medicine, Temple University School of Medicine

Elliot Goldberg, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, and American College of Rheumatology

Disclosure: Nothing to disclose.

Scott D Hodges, DO Consulting Surgeon, Department of Orthopedic Surgery, Center for Sports Medicine and Orthopedics

Scott D Hodges, DO is a member of the following medical societies: American Academy of Disability Evaluating Physicians, American Medical Association, American Osteopathic Association, American Spinal Injury Association, North American Spine Society, Southern Medical Association, Southern Orthopaedic Association, and Tennessee Medical Association

Disclosure: Medtronic Royalty Consulting; Biomet Spine Royalty Consulting

S Craig Humphreys, MD Orthopedic Spine Surgeon, Department of Orthopedic Surgery, Center for Sports Medicine and Orthopedics

S Craig Humphreys, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Orthopaedic Surgeons, American Medical Association, American Spinal Injury Association, North American Spine Society, Southern Medical Association, Southern Orthopaedic Association, and Tennessee Medical Association

Disclosure: Nothing to disclose.

James F Kellam, MD Vice-Chair, Department of Orthopedic Surgery, Director of Orthopedic Trauma and Education, Carolinas Medical Center

James F Kellam, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, Orthopaedic Trauma Association, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Kristine M Lohr, MD, MS Professor, Department of Internal Medicine, Center for the Advancement of Women's Health and Division of Rheumatology, Director, Rheumatology Training Program, University of Kentucky College of Medicine

Kristine M Lohr, MD, MS is a member of the following medical societies: American College of Physicians and American College of Rheumatology

Disclosure: Nothing to disclose.

William O Shaffer, MD Professor, Vice-Chairman and Residency Program Director, Department of Orthopedic Surgery, University of Kentucky at Lexington

William O Shaffer, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Orthopaedic Association, International Society for the Study of the Lumbar Spine, Kentucky Medical Association, Kentucky Orthopaedic Society, North American Spine Society, Southern Medical Association, and Southern Orthopaedic Association

Disclosure: DePuySpine 1997-2007 (not presently) Royalty Consulting; DePuySpine 2002-2007 (closed) Grant/research funds SacroPelvic Instrumentation Biomechanical Study; DePuyBiologics 2005-2008 (closed) Grant/research funds Healos study just closed; DePuySpine 2009 Consulting fee Design of Offset Modification of Expedium

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References

  1. Passalent LA, Soever LJ, O'Shea FD, Inman RD. Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. J Rheumatol. 2010 Apr. 37(4):835-41. [View Abstract]
  2. Jones SD, Koh WH, Steiner A, Garrett SL, Calin A. Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors. J Rheumatol. 1996 Mar. 23(3):487-90. [View Abstract]
  3. Mengshoel AM, Førre O. Pain and fatigue in patients with rheumatic disorders. Clin Rheumatol. 1993 Dec. 12(4):515-21. [View Abstract]
  4. van der Linden S, van der Heijde D. Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am. 1998 Nov. 24(4):663-76, vii. [View Abstract]
  5. Collantes-Estevez E, Cisnal del Mazo A, Munoz-Gomariz E. Assessment of 2 systems of spondyloarthropathy diagnostic and classification criteria (Amor and ESSG) by a Spanish multicenter study. European Spondyloarthropathy Study Group. J Rheumatol. 1995 Feb. 22(2):246-51. [View Abstract]
  6. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991 Oct. 34(10):1218-27. [View Abstract]
  7. van der Heijde D, Spoorenberg A. Plain radiographs as an outcome measure in ankylosing spondylitis. J Rheumatol. 1999 Apr. 26(4):985-7. [View Abstract]
  8. Naredo E, Batlle-Gualda E, García-Vivar ML, García-Aparicio AM, Fernández-Sueiro JL, Fernández-Prada M, et al. Power Doppler ultrasonography assessment of entheses in spondyloarthropathies: response to therapy of entheseal abnormalities. J Rheumatol. 2010 Oct. 37(10):2110-7. [View Abstract]
  9. Vinson EN, Major NM. MR imaging of ankylosing spondylitis. Semin Musculoskelet Radiol. 2003 Jun. 7(2):103-13. [View Abstract]
  10. Geijer M, Gothlin GG, Gothlin JH. The clinical utility of computed tomography compared to conventional radiography in diagnosing sacroiliitis. A retrospective study on 910 patients and literature review. J Rheumatol. 2007 Jul. 34(7):1561-5. [View Abstract]
  11. Van Royen BJ, De Gast A. Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment. Ann Rheum Dis. 1999 Jul. 58(7):399-406. [View Abstract]
  12. Shih LY, Chen TH, Lo WH, Yang DJ. Total hip arthroplasty in patients with ankylosing spondylitis: longterm followup. J Rheumatol. 1995 Sep. 22(9):1704-9. [View Abstract]
  13. Cawley MI, Chalmers TM, Ball J. Destructive lesions of vertebral bodies in ankylosing spondylitis. Ann Rheum Dis. 1971 Sep. 30(5):539-40. [View Abstract]
  14. Hanson JA, Mirza S. Predisposition for spinal fracture in ankylosing spondylitis. AJR Am J Roentgenol. 2000 Jan. 174(1):150. [View Abstract]
  15. Hunter T. The spinal complications of ankylosing spondylitis. Semin Arthritis Rheum. 1989 Dec. 19(3):172-82. [View Abstract]
  16. Sutherland RI, Matheson D. Inflammatory involvement of vertebrae in ankylosing spondylitis. J Rheumatol. 1975 Sep. 2(3):296-302. [View Abstract]
  17. van der Linden S, van der Heijde D. Clinical aspects, outcome assessment, and management of ankylosing spondylitis and postenteric reactive arthritis. Curr Opin Rheumatol. 2000 Jul. 12(4):263-8. [View Abstract]
  18. Schlosstein L, Terasaki PI, Bluestone R, et al. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med. 1973 Apr 5. 288(14):704-6. [View Abstract]
  19. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet. 1973 Apr 28. 1(7809):904-7. [View Abstract]
  20. Caffrey MF, James DC. Human lymphocyte antigen association in ankylosing spondylitis. Nature. 1973 Mar 9. 242(5393):121. [View Abstract]
  21. Alvarez I, López de Castro JA. HLA-B27 and immunogenetics of spondyloarthropathies. Curr Opin Rheumatol. 2000 Jul. 12(4):248-53. [View Abstract]
  22. McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet. 1998 Oct 3. 352(9134):1137-40. [View Abstract]
  23. Muñoz-Villanueva MC, Muñoz-Gomariz E, Escudero-Contreras A, et al. Biological and clinical markers of disease activity in ankylosing spondylitis. J Rheumatol. 2003 Dec. 30(12):2729-32. [View Abstract]
  24. Palazzi C, Olivieri I, D'Amico E, Pennese E, Petricca A. Management of reactive arthritis. Expert Opin Pharmacother. 2004 Jan. 5(1):61-70. [View Abstract]
  25. McGonagle D, Emery P. Enthesitis, osteitis, microbes, biomechanics, and immune reactivity in ankylosing spondylitis. J Rheumatol. 2000 Oct. 27(10):2302-4. [View Abstract]
  26. O'Neill TW, Bresnihan B. The heart in ankylosing spondylitis. Ann Rheum Dis. 1992 Jun. 51(6):705-6. [View Abstract]
  27. Khan MA. Update on spondyloarthropathies. Ann Intern Med. 2002 Jun 18. 136(12):896-907. [View Abstract]
  28. Wordsworth P. Genes in the spondyloarthropathies. Rheum Dis Clin North Am. 1998 Nov. 24(4):845-63. [View Abstract]
  29. Reveille JD. The genetic basis of ankylosing spondylitis. Curr Opin Rheumatol. 2006 Jul. 18(4):332-41. [View Abstract]
  30. Brionez TF, Reveille JD. The contribution of genes outside the major histocompatibility complex to susceptibility to ankylosing spondylitis. Curr Opin Rheumatol. 2008 Jul. 20(4):384-91. [View Abstract]
  31. Brown MA. Breakthroughs in genetic studies of ankylosing spondylitis. Rheumatology (Oxford). 2008 Feb. 47(2):132-7. [View Abstract]
  32. Reveille JD, Ball EJ, Khan MA. HLA-B27 and genetic predisposing factors in spondyloarthropathies. Curr Opin Rheumatol. 2001 Jul. 13(4):265-72. [View Abstract]
  33. Jaakkola E, Herzberg I, Laiho K, Barnardo MC, Pointon JJ, Kauppi M, et al. Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis. 2006 Jun. 65(6):775-80. [View Abstract]
  34. Reveille JD, Arnett FC. Spondyloarthritis: update on pathogenesis and management. Am J Med. 2005 Jun. 118(6):592-603. [View Abstract]
  35. van Gaalen FA, Verduijn W, Roelen DL, Böhringer S, Huizinga TW, van der Heijde DM, et al. Epistasis between two HLA antigens defines a subset of individuals at a very high risk for ankylosing spondylitis. Ann Rheum Dis. 2012 Aug 21. [View Abstract]
  36. Ebringer A. The relationship between Klebsiella infection and ankylosing spondylitis. Baillieres Clin Rheumatol. 1989 Aug. 3(2):321-38. [View Abstract]
  37. Timms AE, Crane AM, Sims AM, Cordell HJ, Bradbury LA, Abbott A, et al. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am J Hum Genet. 2004 Oct. 75(4):587-95. [View Abstract]
  38. Maksymowych WP, Rahman P, Reeve JP, Gladman DD, Peddle L, Inman RD. Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. Arthritis Rheum. 2006 Mar. 54(3):974-85. [View Abstract]
  39. Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007 Nov. 39(11):1329-37. [View Abstract]
  40. Rahman P, Inman RD, Gladman DD, Reeve JP, Peddle L, Maksymowych WP. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum. 2008 Apr. 58(4):1020-5. [View Abstract]
  41. Rueda B, Orozco G, Raya E, Fernandez-Sueiro JL, Mulero J, Blanco FJ, et al. The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. Ann Rheum Dis. 2008 Oct. 67(10):1451-4. [View Abstract]
  42. Karaderi T, Harvey D, Farrar C, Appleton LH, Stone MA, Sturrock RD, et al. Association between the interleukin 23 receptor and ankylosing spondylitis is confirmed by a new UK case-control study and meta-analysis of published series. Rheumatology (Oxford). 2009 Apr. 48(4):386-9. [View Abstract]
  43. Layh-Schmitt G, Colbert RA. The interleukin-23/interleukin-17 axis in spondyloarthritis. Curr Opin Rheumatol. 2008 Jul. 20(4):392-7. [View Abstract]
  44. Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell. 1990 Nov 30. 63(5):1099-112. [View Abstract]
  45. Khare SD, Luthra HS, David CS. Animal models of human leukocyte antigen B27-linked arthritides. Rheum Dis Clin North Am. 1998 Nov. 24(4):883-94, xi-xii. [View Abstract]
  46. Lories RJ. Animal models of spondyloarthritis. Curr Opin Rheumatol. 2006 Jul. 18(4):342-6. [View Abstract]
  47. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998 Jan. 41(1):58-67. [View Abstract]
  48. Trontzas P, Andrianakos A, Miyakis S, et al. Seronegative spondyloarthropathies in Greece: a population-based study of prevalence, clinical pattern, and management. The ESORDIG study. Clin Rheumatol. 2005 Nov. 24(6):583-9. [View Abstract]
  49. De Angelis R, Salaffi F, Grassi W. Prevalence of spondyloarthropathies in an Italian population sample: a regional community-based study. Scand J Rheumatol. 2007 Jan-Feb. 36(1):14-21. [View Abstract]
  50. Taurog JD. The mystery of HLA-B27: if it isn't one thing, it's another. Arthritis Rheum. 2007 Aug. 56(8):2478-81. [View Abstract]
  51. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007 Apr 21. 369(9570):1379-90. [View Abstract]
  52. Feldtkeller E, Khan MA, van der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int. 2003 Mar. 23(2):61-6. [View Abstract]
  53. Dincer U, Cakar E, Kiralp MZ, Dursun H. Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol. 2008 Apr. 27(4):457-62. [View Abstract]
  54. Rezaian MM, Brent LH. Undifferentiated spondyloarthropathy: Seven-year follow-up study of 357 patients. Arthritis Rheum. 2001. 44:S93.
  55. Lee W, Reveille JD, Davis JC Jr, et al. Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis. 2007 May. 66(5):633-8. [View Abstract]
  56. Singh DK, Magrey M. Racial Differences in Clinical Features and Co-morbidities In Ankylosing Spondylitis in the United States. J Rheumatol. 2019 Sep 1. [View Abstract]
  57. Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol. 2002 Nov-Dec. 20(6 Suppl 28):S16-22. [View Abstract]
  58. Ringsdal VS, Helin P. Ankylosing spondylitis--education, employment and invalidity. Dan Med Bull. 1991 Jun. 38(3):282-4. [View Abstract]
  59. Wordsworth BP, Mowat AG. A review of 100 patients with ankylosing spondylitis with particular reference to socio-economic effects. Br J Rheumatol. 1986 May. 25(2):175-80. [View Abstract]
  60. McGuigan LE, Hart HH, Gow PJ, Kidd BL, Grigor RR, Moore TE. Employment in ankylosing spondylitis. Ann Rheum Dis. 1984 Aug. 43(4):604-6. [View Abstract]
  61. Lehtinen K. Working ability of 76 patients with ankylosing spondylitis. Scand J Rheumatol. 1981. 10(4):263-5. [View Abstract]
  62. Verstappen SM, Watson KD, Lunt M, McGrother K, Symmons DP, Hyrich KL. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2010 Aug. 49(8):1570-7. [View Abstract]
  63. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol. 1997 Jul. 36(7):766-71. [View Abstract]
  64. Guillemin F, Briançon S, Pourel J, Gaucher A. Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis. Possible predictive factors. Arthritis Rheum. 1990 Jul. 33(7):1001-6. [View Abstract]
  65. Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am. 1998 Nov. 24(4):737-51, viii. [View Abstract]
  66. Carette S, Graham D, Little H, Rubenstein J, Rosen P. The natural disease course of ankylosing spondylitis. Arthritis Rheum. 1983 Feb. 26(2):186-90. [View Abstract]
  67. Sampaio-Barros PD, Bertolo MB, Kraemer MH, et al. Undifferentiated spondyloarthropathies: a 2-year follow-up study. Clin Rheumatol. 2001. 20(3):201-6. [View Abstract]
  68. Mattey DL, Dawson SR, Healey EL, Packham JC. Relationship Between Smoking and Patient-reported Measures of Disease Outcome in Ankylosing Spondylitis. J Rheumatol. 2011 Dec. 38(12):2608-15. [View Abstract]
  69. O'Shea FD, Riarh R, Anton A, Inman RD. Assessing back pain: does the Oswestry Disability Questionnaire accurately measure function in ankylosing spondylitis?. J Rheumatol. 2010 Jun. 37(6):1211-3. [View Abstract]
  70. Calin A, Porta J, Fries JF, et al. Clinical history as a screening test for ankylosing spondylitis. JAMA. 1977 Jun 13. 237(24):2613-4. [View Abstract]
  71. Rudwaleit M, Metter A, Listing J, et al. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum. 2006 Feb. 54(2):569-78. [View Abstract]
  72. Sieper J, van der Heijde D, Landewé R, Brandt J, Burgos-Vagas R, Collantes-Estevez E, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis. 2009 Jun. 68 (6):784-8. [View Abstract]
  73. Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol. 2002 Jul. 14(4):337-41. [View Abstract]
  74. Ali A, Samson CM. Seronegative spondyloarthropathies and the eye. Curr Opin Ophthalmol. 2007 Nov. 18(6):476-80. [View Abstract]
  75. Burgos-Vargas R. The juvenile-onset spondyloarthritides. Rheum Dis Clin North Am. 2002 Aug. 28(3):531-60, vi. [View Abstract]
  76. Tse SM, Laxer RM. Juvenile spondyloarthropathy. Curr Opin Rheumatol. 2003 Jul. 15(4):374-9. [View Abstract]
  77. Zeidler H, Mau W, Khan MA. Undifferentiated spondyloarthropathies. Rheum Dis Clin North Am. 1992 Feb. 18(1):187-202. [View Abstract]
  78. Amor B, Dougados M, Mijiyawa M. [Criteria of the classification of spondylarthropathies]. Rev Rhum Mal Osteoartic. 1990 Feb. 57(2):85-9. [View Abstract]
  79. Rasker JJ, Prevo RL, Lanting PJ. Spondylodiscitis in ankylosing spondylitis, inflammation or trauma? A description of six cases. Scand J Rheumatol. 1996. 25(1):52-7. [View Abstract]
  80. Dihlmann W, Delling G. Discovertebral destructive lesions (so called Andersson lesions) associated with ankylosing spondylitis. Skel Radiol. 1978. 3:10-6.
  81. Agarwal AK, Reidbord HE, Kraus DR, Eisenbeis CH Jr. Variable histopathology of discovertebral lesion (spondylodiscitis) of ankylosing spondylitis. Clin Exp Rheumatol. 1990 Jan-Feb. 8(1):67-9. [View Abstract]
  82. Lipton S, Deodhar A. The New ASAS Classification Criteria for Axial and Peripheral Spondyloarthritis. Medscape Medical News. Available at http://www.medscape.com/viewarticle/776097_5. Accessed: November 4, 2014.
  83. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011 Jan. 70(1):25-31. [View Abstract]
  84. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009 Jun. 68 (6):777-83. [View Abstract]
  85. van der Heijde D, Landewé R. Imaging in spondylitis. Curr Opin Rheumatol. 2005 Jul. 17(4):413-7. [View Abstract]
  86. [Guideline] Mandl P, Navarro-Compán V, Terslev L, et al. EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis. 2015 Apr 2. [View Abstract]
  87. Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol. 1999 Apr. 26(4):966-70. [View Abstract]
  88. Dougados M, Gueguen A, Nakache JP, et al. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol. 1999 Apr. 26(4):971-4. [View Abstract]
  89. Anwar F, Al-Khayer A, Joseph G, Fraser MH, Jigajinni MV, Allan DB. Delayed presentation and diagnosis of cervical spine injuries in long-standing ankylosing spondylitis. Eur Spine J. 2011 Mar. 20(3):403-7. [View Abstract]
  90. Baraliakos X, Hermann KG, Landewé R, Listing J, Golder W, Brandt J, et al. Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis. 2005 Aug. 64(8):1141-4. [View Abstract]
  91. Hermann KG, Landewé RB, Braun J, van der Heijde DM. Magnetic resonance imaging of inflammatory lesions in the spine in ankylosing spondylitis clinical trials: is paramagnetic contrast medium necessary?. J Rheumatol. 2005 Oct. 32(10):2056-60. [View Abstract]
  92. Kim NR, Choi JY, Hong SH, Jun WS, Lee JW, Choi JA, et al. "MR corner sign": value for predicting presence of ankylosing spondylitis. AJR Am J Roentgenol. 2008 Jul. 191(1):124-8. [View Abstract]
  93. Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Østergaard M, Lambert RG. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum. 2009 Jan. 60(1):93-102. [View Abstract]
  94. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006 Apr. 65(4):442-52. [View Abstract]
  95. Halm H, Metz-Stavenhagen P, Zielke K. Results of surgical correction of kyphotic deformities of the spine in ankylosing spondylitis on the basis of the modified arthritis impact measurement scales. Spine (Phila Pa 1976). 1995 Jul 15. 20(14):1612-9. [View Abstract]
  96. Hunter T, Dubo HI. Spinal fractures complicating ankylosing spondylitis. A long-term followup study. Arthritis Rheum. 1983 Jun. 26(6):751-9. [View Abstract]
  97. Carron P, Varkas G, Renson T, Colman R, Elewaut D, Van den Bosch F. High rate of drug-free remission after induction therapy with golimumab in early peripheral spondyloarthritis. Arthritis Rheumatol. 2018 May 27. [View Abstract]
  98. Lewis R. TNF Inhibitor Induces Drug-Free Remission in Early Spondyloarthritis. Medscape Medical News. Available at https://www.medscape.com/viewarticle/897894?src=soc_fb_180612_mscpedt_news_mdscp_arthritis&faf=1. June 11, 2018; Accessed: June 12, 2018.
  99. Cimzia (certolizumab) [package insert]. Lake Park Drive Smyrna, GA: UCB, Inc. April 2019. Available at
  100. Escalas C, Trijau S, Dougados M. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatology (Oxford). 2010 Jul. 49(7):1317-25. [View Abstract]
  101. Wanders A, Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005 Jun. 52(6):1756-65. [View Abstract]
  102. Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis. 2008 Mar. 67(3):323-9. [View Abstract]
  103. Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol. 2006 Apr. 33(4):722-31. [View Abstract]
  104. Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996 Dec. 39(12):2004-12. [View Abstract]
  105. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999 Nov. 42(11):2325-9. [View Abstract]
  106. Braun J, Pavelka K, Ramos-Remus C, Dimic A, Vlahos B, Freundlich B, et al. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol. 2012 Apr. 39(4):836-40. [View Abstract]
  107. Inman RD, Maksymowych WP. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol. 2010 Jun. 37(6):1203-10. [View Abstract]
  108. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006 Mar. 65(3):316-20. [View Abstract]
  109. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum. 2003 Apr. 48(4):1126-36. [View Abstract]
  110. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002 May 2. 346(18):1349-56. [View Abstract]
  111. Davis JC, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003 Nov. 48(11):3230-6. [View Abstract]
  112. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005 Feb. 52(2):582-91. [View Abstract]
  113. Braun J, Landewé R, Hermann KG, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum. 2006 May. 54(5):1646-52. [View Abstract]
  114. Gengenbacher M, Sebald HJ, Villiger PM, Hofstetter W, Seitz M. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2008 May. 67(5):620-4. [View Abstract]
  115. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006 Jul. 54(7):2136-46. [View Abstract]
  116. Inman RD, Davis JC Jr, Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008 Nov. 58(11):3402-12. [View Abstract]
  117. Medscape News. FDA clears certolizumab (Cimzia) for ankylosing spondylitis. Medscape. Available at http://www.medscape.com/viewarticle/812822. Accessed: October 18, 2013.
  118. Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2013 Sep 6. [View Abstract]
  119. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Emery P, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis. 2006 Nov. 65 Suppl 3:iii2-15. [View Abstract]
  120. Kelly JC. Ankylosing Spondylitis: Prolonged Anti-TNF Stops Damage. Medscape Medical News. Jun 22 2013. Available at http://www.medscape.com/viewarticle/808219. Accessed: July 30, 2013.
  121. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The Impact of TNF-inhibitors on radiographic progression in Ankylosing Spondylitis. Arthritis Rheum. 2013 Jul 1. [View Abstract]
  122. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015 Dec 24. 373 (26):2534-48. [View Abstract]
  123. van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018 Dec 8. 392 (10163):2441-2451. [View Abstract]
  124. Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 2019 Apr. 71 (4):599-611. [View Abstract]
  125. Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev. 2006 Oct 18. CD004524. [View Abstract]
  126. van Denderen JC, van der Paardt M, Nurmohamed MT, de Ryck YM, Dijkmans BA, van der Horst-Bruinsma IE. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis. 2005 Dec. 64(12):1761-4. [View Abstract]
  127. [Guideline] Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2015 Sep 24. [View Abstract]
  128. [Guideline] Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan. 77 (1):3-17. [View Abstract]
  129. van Denderen JC, Visman IM, Nurmohamed MT, Suttorp-Schulten MS, van der Horst-Bruinsma IE. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. J Rheumatol. 2014 Sep. 41(9):1843-8. [View Abstract]
  130. van der Heijde D, Dougados M, Davis J, Weisman MH, Maksymowych W, Braun J, et al. ASsessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum. 2005 Feb. 52(2):386-94. [View Abstract]
  131. Zochling J, Braun J. Assessments in ankylosing spondylitis. Best Pract Res Clin Rheumatol. 2007 Aug. 21(4):699-712. [View Abstract]
  132. Zochling J. Assessment and treatment of ankylosing spondylitis: current status and future directions. Curr Opin Rheumatol. 2008 Jul. 20(4):398-403. [View Abstract]
  133. Blizzard DJ, Penrose CT, Sheets CZ, Seyler TM, Bolognesi MP, Brown CR. Ankylosing Spondylitis Increases Perioperative and Postoperative Complications After Total Hip Arthroplasty. J Arthroplasty. 2017 Mar 27. [View Abstract]
  134. Dagfinrud H, Kvien TK, Hagen KB. The Cochrane review of physiotherapy interventions for ankylosing spondylitis. J Rheumatol. 2005 Oct. 32(10):1899-906. [View Abstract]
  135. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev. 2008 Jan 23. CD002822. [View Abstract]
  136. Zhao Q, Dong C, Liu Z, Li M, Wang J, Yin Y, et al. The effectiveness of aquatic physical therapy intervention on disease activity and function of ankylosing spondylitis patients: a meta-analysis. Psychol Health Med. 2019 Sep 2. 1-12. [View Abstract]
  137. Goodman SM, Zhu R, Figgie MP, Huang WT, Mandl LA. Short-term Total Hip Replacement Outcomes in Ankylosing Spondylitis. J Clin Rheumatol. 2014 Oct. 20(7):363-8. [View Abstract]
  138. Hidding A, van der Linden S, Gielen X, et al. Continuation of group physical therapy is necessary in ankylosing spondylitis: results of a randomized controlled trial. Arthritis Care Res. 1994 Jun. 7(2):90-6. [View Abstract]
  139. Kisacik B, Tufan A, Kalyoncu U, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008 May. 75(3):291-4. [View Abstract]
  140. Kraag G, Stokes B, Groh J, Helewa A, Goldsmith C. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis--a randomized controlled trial. J Rheumatol. 1990 Feb. 17(2):228-33. [View Abstract]

Anteroposterior radiograph of sacroiliac joint of patient with ankylosing spondylitis. Bilateral sacroiliitis with sclerosis can be observed.

Family of spondyloarthropathies and HLA-B27 associated diseases

Patient with ankylosing spondylitis affecting cervical and upper thoracic spine. Patient's spine has been fused in flexed position.

Posterior view of patient with ankylosing spondylitis affecting cervical and upper thoracic spine. Patient's spine has been fused in flexed position.

ASAS Classification Criteria for Axial Spondyloarthropathy.

ASAS Classification Criteria for Peripheral Spondyloarthropathy.

Anteroposterior radiograph of sacroiliac joint of patient with ankylosing spondylitis. Bilateral sacroiliitis with sclerosis can be observed.

Anteroposterior radiograph of spine of patient with ankylosing spondylitis. Ossification of anulus fibrosus at multiple levels and squaring of vertebral bodies can be observed.

Anteroposterior radiograph of spine of patient with ankylosing spondylitis.

Anteroposterior (left) and lateral (right) radiographs of patient with ankylosing spondylitis.

Anteroposterior radiograph of spine of patient with ankylosing spondylitis. Ossification of anulus fibrosus can be observed at multiple levels, which has led to fusion of spine with abnormal curvature.

This radiograph of the lumbar spine of a patient with end-stage ankylosing spondylitis shows bridging syndesmophytes, resulting in bamboo spine.

This radiograph of the cervical spine of a patient with ankylosing spondylitis shows fusion of vertebral bodies due to bridging syndesmophytes.

Radiographs of hand (top) and arm (bottom) of patient with peripheral involvement of ankylosing spondylitis. Fusion of joint spaces and deformity can be observed.

Radiograph shows vertebral fracture in patient with ankylosing spondylitis.

Sagittal MRI of thoracolumbar spine of a patient with ankylosing spondylitis. Degenerative disc disease and bridging osteophytes can be observed at multiple levels.

This 15-year-old female patient presented with recent onset of right-sided low back pain. Plain radiography findings were normal.

MRI of the same patient whose radiography findings were normal (previous image). She underwent further evaluation, including MRI. The MRI (short tau inversion recovery [STIR]) showed increased sinal intensity in the right sacroiliac joint, revealing sacroiliitis. Other laboratory study findings were essentially normal. The patient was started on indomethacin and rapidly improved.

This 15-year-old female patient presented with recent onset of right-sided low back pain. Plain radiography findings were normal.

MRI of the same patient whose radiography findings were normal (previous image). She underwent further evaluation, including MRI. The MRI (short tau inversion recovery [STIR]) showed increased sinal intensity in the right sacroiliac joint, revealing sacroiliitis. Other laboratory study findings were essentially normal. The patient was started on indomethacin and rapidly improved.

Patient with ankylosing spondylitis affecting cervical and upper thoracic spine. Patient's spine has been fused in flexed position.

Posterior view of patient with ankylosing spondylitis affecting cervical and upper thoracic spine. Patient's spine has been fused in flexed position.

Anteroposterior radiograph of sacroiliac joint of patient with ankylosing spondylitis. Bilateral sacroiliitis with sclerosis can be observed.

Anteroposterior radiograph of spine of patient with ankylosing spondylitis. Ossification of anulus fibrosus can be observed at multiple levels, which has led to fusion of spine with abnormal curvature.

Anteroposterior radiograph of spine of patient with ankylosing spondylitis. Ossification of anulus fibrosus at multiple levels and squaring of vertebral bodies can be observed.

Anteroposterior radiograph of spine of patient with ankylosing spondylitis.

Anteroposterior (left) and lateral (right) radiographs of patient with ankylosing spondylitis.

Radiographs of hand (top) and arm (bottom) of patient with peripheral involvement of ankylosing spondylitis. Fusion of joint spaces and deformity can be observed.

Sagittal MRI of thoracolumbar spine of a patient with ankylosing spondylitis. Degenerative disc disease and bridging osteophytes can be observed at multiple levels.

Radiograph shows vertebral fracture in patient with ankylosing spondylitis.

This radiograph of the lumbar spine of a patient with end-stage ankylosing spondylitis shows bridging syndesmophytes, resulting in bamboo spine.

This radiograph of the cervical spine of a patient with ankylosing spondylitis shows fusion of vertebral bodies due to bridging syndesmophytes.

ASAS Classification Criteria for Axial Spondyloarthropathy.

ASAS Classification Criteria for Peripheral Spondyloarthropathy.

Family of spondyloarthropathies and HLA-B27 associated diseases

Population or Disease Entity HLA-B27 –Positive
Healthy whites8%
Healthy African Americans4%
Ankylosing spondylitis (whites)92%
Ankylosing spondylitis (African Americans)50%
Reactive arthritis60-80%
Psoriasis associated with spondylitis60%
IBD associated with spondylitis60%
Isolated acute anterior uveitis50%
Undifferentiated spondyloarthropathy20-25%
Genes Chromosome Location Gene Product/Function
Definitely associated



HLA-B27



IL-1 gene cluster



CYP 2D6



ARTS1 (ERAP1)



IL23R



6p21.3



2q12.1



22q13.2



5q15



1p31.1



Antigen presentation



Modulator of inflammation



Metabolism of xenobiotics



ER aminopeptidase 1



IL-23 receptor



Possibly associated



ANKH



HLA-DRB1



5p15



6p21.3



Ectopic mineralization



Antigen presentation



Not associated



TGF-ß, MMP3, IL-10, IL-6, Ig allotypes, TCR, TLR4, NOD2/CARD15, CD14, NFßBIL1, PTPN22, etc



MultipleMultiple
Inclusion Criteria Exclusion Criteria
Inflammatory back pain1 pointDiagnosis of specific spondyloarthropathy
Unilateral buttock pain1 pointSacroiliitis on radiograph = grade 2
Alternating buttock pain2 pointsPrecipitating genitourinary/gastrointestinal infection
Enthesitis2 pointsPsoriasis
Peripheral arthritis2 pointsKeratoderma blennorrhagicum
Dactylitis (sausage digit)2 pointsInflammatory bowel disease (Crohn disease or ulcerative colitis)
Acute anterior uveitis2 pointsPositive rheumatoid factor
HLA-B27 positive or family history of spondyloarthropathy2 pointsPositive antinuclear antibody, titer > 1:80
Good response to nonsteroidal anti-inflammatory drugs2 points 
Diagnosis of spondyloarthropathy with 6 or more points
Clinical or Laboratory Feature Frequency
Inflammatory back pain90%
Buttock pain80%
Enthesitis75%
Peripheral arthritis40%
Dactylitis (sausage digits)20%
Acute anterior uveitis1-2%
Fatigue55%
Elevated ESR32%
HLA-B27 positive25%
ESR = erythrocyte sedimentation rate.
ESSG Criteria Amor Criteria*
Inflammatory spinal pain or synovitis and one of the following:Inflammatory back pain1 point
Alternating buttock painUnilateral buttock pain1 point
EnthesitisAlternating buttock pain2 points
SacroiliitisEnthesitis2 points
IBDPeripheral arthritis2 points
Positive family history of spondyloarthropathyDactylitis (sausage digit)2 points
 Acute anterior uveitis2 points
 HLA-B27 positive or family history of spondyloarthropathy2 points
 Good response to NSAIDs2 points
*Diagnosis of spondyloarthropathy with 6 or more points.



European Spondyloarthropathy Study Group (ESSG); IBD = inflammatory bowel disease; NSAID = nonsteroidal anti-inflammatory drug.



New York Criteria Rome Criteria
  • Low back pain with inflammatory characteristics
  • Limitation of lumbar spine motion in sagittal and frontal planes
  • Decreased chest expansion
  • Bilateral sacroiliitis grade 2 or higher
  • Unilateral sacroiliitis grade 3 or higher
  • Low back pain and stiffness for >3 months that is not relieved by rest
  • Pain and stiffness in the thoracic region
  • Limited motion in the lumbar spine
  • Limited chest expansion
  • History of uveitis
Definite ankylosing spondylitis when the fourth or fifth criterion mentioned presents with any clinical criteriaDiagnosis of ankylosing spondylitis when any clinical criteria present with bilateral sacroiliitis grade 2 or higher